1. Charlotte’s Web: This strain is known for its high CBD content and is often used to treat seizures and epilepsy. 2. Sour Tsunami: Another high-CBD strain, Sour Tsunami is used to alleviate pain, stress, and inflammation. 3. ACDC: This strain is used to treat mental health conditions like anxiety and depression, as well as chronic pain and inflammation. 4. Ringo’s Gift: A hybrid that delivers a balanced blend of CBD and THC, it’s used for a range of conditions, including anxiety, stress, and physical discomfort. 5. Harlequin: This strain has a high CBD content that aids in treating pain and anxiety without a heavy psychoactive high. 6. Blue Dream: Mostly used for patients suffering from depression, nausea, and pain. 7. Jack Herer: It’s used for managing anxiety, stress, and depression. 8. Cannatonic: This strain is often used for treating anxiety, migraines, and pain. 9. Northern Lights: It’s used for insomnia, stress, and pain. 10. White Widow: Known for treating chronic pain, migraines, and stress disorders. 11. Purple Kush: It’s often used to manage chronic pain, insomnia, and anxiety. 12. Granddaddy Purple: This strain helps with chronic pain, stress, insomnia, and muscle spasms. 13. Blackberry Kush: Helpful for those dealing with pain, insomnia, and stress. 14. Bubba Kush: It’s used for reducing stress, pain, and insomnia. 15. Afghan Kush: This is used for chronic pain, stress, and insomnia. 16. Super Silver Haze: Known for managing depression, stress, and pain. 17. Skywalker: Best for treating insomnia, pain, and stress. 18. Pineapple Express: It’s used for mood elevation and pain relief. 19. Girl Scout Cookies: Mainly used for pain relief, appetite stimulation, and nausea alleviation. 20. Chocolope: It’s often used to treat stress, depression, and fatigue. 21. Strawberry Cough: This strain is used for managing stress, anxiety, and depression. 22. Lemon Haze: Known for uplifting mood, it also helps in stress and depression. 23. Master Kush: It’s used for treating stress, depression, and chronic pain. 24. OG Kush: Primarily used to treat stress, depression, and pain. 25. Amnesia Haze: This strain is used for mental health conditions like depression and anxiety. 26. Trainwreck: Works well for relieving stress, depression, and pain. 27. Blue Cheese: It’s used for pain and stress relief, as well as a sleep aid. 28. Durban Poison: It’s often used to treat depression, stress, and fatigue. 29. Chemdawg: This strain is used for relieving stress, pain, and depression. 30. Death Star: It’s used for insomnia, pain, and stress. 31. Romulan: Known for treating muscle spasms, nerve damage, and chronic pain. 32. LA Confidential: It’s used for anxiety, ADD/ADHD, and PTSD. 33. Tahoe OG: It’s used for insomnia, pain, and stress. 34. Purple Urkle: This strain is used for insomnia and stress. 35. Alien OG: It’s used for stress, depression, and pain. 36. God’s Gift: Known for treating chronic pain, stress, and insomnia. 37. Headband: This strain is used for chronic pain, migraines, and anxiety. 38. Maui Wowie: It’s used for stress, depression, and pain. 39. Bruce Banner: This strain is used for stress, depression, and pain. 40. Alaskan Thunder Fuck: It’s used for stress, depression, and pain. 41. The White: Known for treating insomnia, pain, and loss of appetite. 42. Agent Orange: This strain is used for stress, depression, and pain. 43. Golden Goat: It’s used for stress, depression, and pain. 44. Banana Kush: This strain is used for stress, depression, and pain. 45. Green Crack: It’s used for fatigue, stress, and depression. 46. Super Lemon Haze: This strain is used for stress, depression, and fatigue. 47. Chernobyl: It’s used for depression, stress, and pain. 48. Blueberry: This strain is used for pain, stress, and insomnia. 49. Ghost Train Haze: It’s used for depression, pain, and fatigue. 50. Gelato: This strain is used for stress, depression, and pain. Please remember that the effects of different cannabis strains can vary between individuals. Always consult with a healthcare provider before trying any new treatment.

1. ACDC: This strain is known for its high CBD content and low THC content, making it ideal for those who want the medicinal benefits of cannabis without the psychoactive effects¹.
2. Harlequin: This strain has a high CBD to THC ratio, which makes it a popular choice for those seeking relief from pain, anxiety, and inflammation¹.
3. Cannatonic: This strain is known for its high CBD content and low THC content, making it a popular choice for those seeking relief from pain, muscle spasms, and anxiety¹.
4. Charlotte’s Web: This strain is known for its high CBD content and low THC content, making it a popular choice for those seeking relief from seizures, muscle spasms, and anxiety¹.
5. Girl Scout Cookies: This strain is known for its ability to help with pain, nausea, and appetite loss¹.
6. Blue Dream: This strain is known for its ability to help with pain, depression, and nausea¹.
7. OG Kush: This strain is known for its ability to help with pain, anxiety, and depression¹.
8. Sour Diesel: This strain is known for its ability to help with pain, depression, and anxiety¹.
9. Granddaddy Purple: This strain is known for its ability to help with pain, insomnia, and stress¹.
10. Bubba Kush: This strain is known for its ability to help with pain, insomnia, and stress¹.

Please note that this is not an exhaustive list, and the effectiveness of each strain may vary depending on the individual. It is important to consult with a medical professional before using medicinal cannabis to ensure that it is safe and effective for you¹.

Learn more:

1. plantsofmerit.org2. medbud.wiki3. sensiseeds.com4. 10buds.com

Here are some more medicinal cannabis strains:

1. Jack Herer: This strain is known for its ability to help with depression, fatigue, and stress¹.
2. Purple Kush: This strain is known for its ability to help with pain, insomnia, and stress¹.
3. Northern Lights: This strain is known for its ability to help with pain, anxiety, and depression¹.
4. White Widow: This strain is known for its ability to help with pain, depression, and anxiety¹.
5. Super Silver Haze: This strain is known for its ability to help with pain, depression, and fatigue¹.
6. Cherry Pie: This strain is known for its ability to help with pain, anxiety, and depression¹.
7. Durban Poison: This strain is known for its ability to help with depression, fatigue, and stress¹.
8. Blueberry: This strain is known for its ability to help with pain, insomnia, and stress¹.
9. Tahoe OG Kush: This strain is known for its ability to help with pain, depression, and anxiety¹.
10. Gorilla Glue: This strain is known for its ability to help with pain, depression, and anxiety¹.

Please note that the effectiveness of each strain may vary depending on the individual. It is important to consult with a medical professional before using medicinal cannabis to ensure that it is safe and effective for you¹.

Learn more:

1. plantsofmerit.org2. medbud.wiki3. leafwell.com4. zamnesia.com5. 10buds.com

Here are some more medicinal cannabis strains:

1. Afghan Kush: This strain is known for its ability to help with pain, stress, and insomnia¹.
2. Cannabis Ruderalis: This strain is known for its ability to help with anxiety, depression, and chronic pain¹.
3. Critical Mass: This strain is known for its ability to help with pain, stress, and insomnia¹.
4. G13: This strain is known for its ability to help with pain, stress, and depression¹.
5. God’s Gift: This strain is known for its ability to help with pain, stress, and insomnia¹.
6. Green Crack: This strain is known for its ability to help with fatigue, depression, and stress¹.
7. Hindu Kush: This strain is known for its ability to help with pain, stress, and insomnia¹.
8. Master Kush: This strain is known for its ability to help with pain, stress, and depression¹.
9. Pineapple Express: This strain is known for its ability to help with pain, depression, and anxiety¹.
10. Trainwreck: This strain is known for its ability to help with pain, stress, and depression¹.
11.  Please note that the effectiveness of each strain may vary depending on the individual. It is important to consult with a medical professional before using medicinal cannabis to ensure that it is safe and effective for you¹.

Learn more:

1. plantsofmerit.org2. medbud.wiki3. leafwell.com4. zamnesia.com5. 10buds.com

Here are some more medicinal cannabis strains:

1. Blackberry Kush: This strain is known for its ability to help with pain, insomnia, and stress¹.
2. Chernobyl: This strain is known for its ability to help with depression, fatigue, and stress¹.
3. Death Star: This strain is known for its ability to help with pain, depression, and anxiety¹.
4. Grape Ape: This strain is known for its ability to help with pain, insomnia, and stress¹.
5. Jillybean: This strain is known for its ability to help with depression, fatigue, and stress¹.
6. Lemon Haze: This strain is known for its ability to help with pain, depression, and anxiety¹.
7. Maui Wowie: This strain is known for its ability to help with depression, fatigue, and stress¹.
8. Purple Haze: This strain is known for its ability to help with pain, depression, and anxiety¹.
9. Sour OG: This strain is known for its ability to help with pain, depression, and anxiety¹.
10. Tangerine Dream: This strain is known for its ability to help with depression, fatigue, and stress¹.

Please note that the effectiveness of each strain may vary depending on the individual. It is important to consult with a medical professional before using medicinal cannabis to ensure that it is safe and effective for you¹.

Learn more:

1. plantsofmerit.org2. medbud.wiki3. leafwell.com4. zamnesia.com5. 10buds.com

Here are some more medicinal cannabis strains:

1. AK-47: This strain is known for its ability to help with depression, stress, and pain¹.
2. Amnesia Haze: This strain is known for its ability to help with depression, fatigue, and stress¹.
3. Blue Cheese: This strain is known for its ability to help with pain, depression, and anxiety¹.
4. Chemdawg: This strain is known for its ability to help with pain, depression, and anxiety¹.
5. Chocolope: This strain is known for its ability to help with depression, fatigue, and stress¹.
6. Grapefruit: This strain is known for its ability to help with depression, fatigue, and stress¹.
7. Haze: This strain is known for its ability to help with depression, fatigue, and stress¹.
8. Kali Mist: This strain is known for its ability to help with depression, fatigue, and stress¹.
9. Lavender: This strain is known for its ability to help with pain, depression, and anxiety¹.
10. Northern Berry: This strain is known for its ability to help with pain, depression, and anxiety¹.

Please note that the effectiveness of each strain may vary depending on the individual. It is important to consult with a medical professional before using medicinal cannabis to ensure that it is safe and effective for you¹.

Learn more:

1. plantsofmerit.org2. medbud.wiki3. leafwell.com4. zamnesia.com5. 10buds.com+1 more

Is cannabis the same as marijuana? People often use the words “cannabis” and “marijuana” interchangeably, but they have slightly different meanings.

“Cannabis” refers to all products derived from the Cannabis sativa plant. This plant contains approximately 540 different chemical compounds.

“Marijuana” specifically refers to parts of or products from the Cannabis sativa plant that have high levels of tetrahydrocannabinol (THC). THC is the compound responsible for the psychoactive effects of marijuana. Some cannabis plants have very low THC levels and are considered “industrial hemp” under U.S. law.

Throughout this guide, we’ll use the term “cannabis” to refer to the Cannabis sativa plant.

What are cannabinoids? Cannabinoids are a group of compounds found in the cannabis plant.

What are the primary cannabinoids? The main cannabinoids are THC and cannabidiol (CBD).

How many cannabinoids are there? In addition to THC and CBD, researchers have identified more than 100 other cannabinoids.

Has the U.S. FDA approved cannabis or cannabinoids for medical use? The FDA has not approved the entire cannabis plant for medical use. However, they have approved certain drugs containing individual cannabinoids.

Epidiolex, which contains a purified form of CBD from cannabis, is approved to treat specific epilepsy syndromes. Marinol and Syndros contain dronabinol (synthetic THC), while Cesamet contains nabilone (a synthetic compound similar to THC). These drugs are FDA-approved to treat nausea and vomiting from cancer chemotherapy. Dronabinol is also used to address appetite loss in people with HIV/AIDS.

Is it legal for dietary supplements or foods to contain THC or CBD? The FDA has determined that products containing THC or CBD cannot be legally sold as dietary supplements. The legality of foods containing THC or CBD depends on state laws and regulations.

Are cannabis or cannabinoids effective in treating health conditions? Cannabinoid-based drugs may help with certain rare forms of epilepsy, chemotherapy-induced nausea and vomiting, and appetite loss associated with HIV/AIDS. Some evidence suggests modest benefits for chronic pain and multiple sclerosis symptoms. However, cannabis is not effective for glaucoma. Research on cannabis and cannabinoids for other conditions is in its early stages.

Is cannabis and CBD safe? Several concerns have been raised about the safety of cannabis and cannabinoids:

• Cannabis use has been linked to an increased risk of motor vehicle accidents.
• Smoking cannabis during pregnancy is associated with lower birth weight.
• Some individuals who use cannabis develop cannabis use disorder, with symptoms like cravings, withdrawal, lack of control, and negative effects on personal and professional responsibilities.
• Adolescents using cannabis are more likely to develop cannabis use disorder than adults.
• Cannabis use is linked to a higher risk of injury in older adults.
• Frequent cannabis use may increase the risk of developing severe mental illnesses in individuals predisposed to such conditions, such as schizophrenia.
• Cannabis may cause orthostatic hypotension (dizziness when standing up), which can increase the risk of fainting and falls.
• The FDA has warned against using vaping products containing THC, as they have been associated with severe lung injuries.

There have been reports of accidental cannabis or cannabinoid ingestion by children, leading to severe illnesses requiring hospitalization. Some long-term, high-dose cannabis users have experienced a condition involving severe vomiting.

Contamination of cannabis and cannabinoid products with microorganisms, pesticides, or other substances has also been reported. Some products contain different cannabinoid levels than what is stated on their labels.

Can CBD be harmful? Over-the-counter CBD products may contain more or less CBD than stated, and they can also contain contaminants like THC. CBD may have side effects, including changes in mood, appetite, and gastrointestinal symptoms. It may also produce cognitive impairment in those who regularly use THC. CBD use has been associated with liver injury, male reproductive harm, and drug interactions.

In summary, while cannabis and cannabinoids show promise for certain medical conditions, their use should be approached with caution due to potential risks and varying regulations. It’s important to consult with healthcare providers and follow state laws regarding their use.

The terms “cannabis” and “marijuana” are often used interchangeably, but they have slightly different meanings. “Cannabis” refers to all products derived from the Cannabis sativa plant, which contains approximately 540 different chemical compounds. “Marijuana” specifically refers to parts of or products from the Cannabis sativa plant that have high levels of tetrahydrocannabinol (THC), the compound responsible for the psychoactive effects of marijuana. Some cannabis plants have very low THC levels and are considered “industrial hemp” under U.S. law ¹.

Cannabinoids are a group of compounds found in the cannabis plant. The main cannabinoids are THC and cannabidiol (CBD), but researchers have identified more than 100 other cannabinoids ¹.

The FDA has not approved the entire cannabis plant for medical use. However, they have approved certain drugs containing individual cannabinoids. Epidiolex, which contains a purified form of CBD from cannabis, is approved to treat specific epilepsy syndromes. Marinol and Syndros contain dronabinol (synthetic THC), while Cesamet contains nabilone (a synthetic compound similar to THC). These drugs are FDA-approved to treat nausea and vomiting from cancer chemotherapy. Dronabinol is also used to address appetite loss in people with HIV/AIDS ¹.

The FDA has determined that products containing THC or CBD cannot be legally sold as dietary supplements. The legality of foods containing THC or CBD depends on state laws and regulations ¹.

Cannabinoid-based drugs may help with certain rare forms of epilepsy, nausea and vomiting from cancer chemotherapy, and appetite loss in people with HIV/AIDS. However, more research is needed to determine the effectiveness of cannabis or cannabinoids in treating other health conditions ¹.

¹: Source: NHS England.

Learn more:

1. legalline.ca2. thehealthsite.com3. nairametrics.com4. msn.com5. goodrx.com6. shutterstock.com

CBPMs are products derived from cannabis that are intended for medicinal purposes. This summary provides essential information for healthcare professionals to assist in prescribing these products. It also outlines the legal framework surrounding CBPMs.

Publication and Content: This document offers guidance and advice for healthcare providers making decisions about the use of CBPMs. It covers the indications for use, product information, prescribing recommendations, and more.

Guidance and Advice: The National Institute for Health and Care Excellence (NICE) has published Technology Appraisals for the use of cannabidiol (Epidyolex®) for specific treatment-resistant epilepsies. NICE has also issued guidelines on cannabis-based products for medicinal use. These include recommendations for individuals dealing with chronic pain, intractable nausea and vomiting, spasticity, and severe treatment-resistant epilepsy.

Specialized Guidance: The British Paediatric Neurology Association (BPNA) has specific guidance on the use of cannabis-based products for pediatric patients with certain severe forms of epilepsy. It recommends Epidiolex® (CBD) as the preferred choice for prescription within its licensed indications. The use of non-licensed cannabis-derived medical products, including artisanal cannabis oils, is not recommended.

Efficacy and Safety: The most robust evidence for the efficacy and safety of CBPMs in childhood epilepsy relates to pure cannabidiol (Epidyolex®). Products containing THC, another compound in cannabis, do not have sufficient evidence for safety or efficacy. There are concerns about the potential adverse effects of THC on the developing brain, particularly with chronic high exposure.

Cannabis Compounds: Cannabis contains numerous chemical constituents, but two of the most researched are tetrahydrocannabinol (THC) and cannabidiol (CBD). THC is the psychoactive component, responsible for the “high” associated with cannabis, while CBD is non-psychoactive.

Regulations and Quality: Pure CBD is not considered a controlled drug under the Misuse of Drugs Act. Products categorized under Schedule 2 may contain varying quantities of THC and CBD, and their quality has not been assessed by regulators. These unlicensed products are available in various forms and are not subject to regulatory review.

E-Learning Package: NHS England offers an e-learning package in collaboration with Health Education England and the University of Birmingham. This resource provides healthcare professionals with information about cannabis and cannabis-based products for medicinal use, including pharmacology, legislation, and therapeutic areas.

Indications for Use: CBPMs can be prescribed for a range of medical conditions. There are licensed products available for intractable nausea and vomiting, MS-related spasticity, and severe treatment-resistant epilepsy. However, most CBPMs are unlicensed, and it is essential to consider the patient’s condition, clinical evidence, and other licensed treatment options when prescribing.

Use in Multiple Sclerosis: The NICE guideline recommends a trial of THC:CBD spray (Sativex®) for treating moderate to severe spasticity in adults with multiple sclerosis if other treatments are ineffective. Sativex® is a licensed product and preferred over unlicensed cannabis-based products.

Use in Chronic Pain: The current evidence for using CBPMs in chronic pain is limited. While some patients may perceive benefits, this has not been fully confirmed in large-scale clinical trials. The safety and long-term efficacy of these products remain uncertain.

Synthetic Cannabinoids: There are three categories of synthetic cannabinoids, some of which are associated with severe harm and are found in illicit street products known as “Spice” and “Black Mamba.” Regulatory bodies are concerned about these compounds, and further research is ongoing.

Cannabidiol (CBD): Cannabidiol oral solution (Epidyolex®) is a licensed medicinal cannabis product proven effective for certain epilepsy syndromes. Pure CBD-based products, including synthetic versions, are not classified as cannabis-based products for medicinal use and are not controlled drugs due to their low THC content.

Quality of Products: Unlicensed medicines are not subject to the same regulatory assessments as licensed medicines, so their quality is not guaranteed. The law change aims to encourage clinical trials and further research.

Clinical Trials: Rescheduling CBPMs makes it easier to conduct clinical trials to gather more evidence regarding their efficacy and safety. The evidence base for these products is still evolving.

Second Opinions: Patients have the option to seek a second opinion, which should be supported by healthcare providers. Protocols are in place for referrals to specialists.

Funding: Unlicensed CBPMs are not routinely commissioned in the NHS. Decisions to prescribe these products are made on a case-by-case basis, considering individual patient clinical needs and safety.

Prescribing Information: CBPMs can only be prescribed by a clinician on the General Medical Council’s Specialist Register. A specialist should consider the relevant GMC guidance and local NHS Trust governance procedures.

Shared Care: Shared care arrangements are under consideration, but any shared care of these products should be based on clinical data and evidence.

Medicinal Cannabis Patient Registry: A patient registry has been launched to collect data on the prescribing of CBPMs, enabling monitoring of patient outcomes and experiences.

Private Prescribing: Private doctors on the GMC specialist register can legally prescribe CBPMs. In the private sector, clinicians are expected to follow similar processes for prescribing unlicensed medicines as in the NHS.

UK Regulations: Prescriptions from outside the UK are not permissible, as the law restricts prescribing of CBPMs to clinicians on the General Medical Council’s Specialist Register.

Monitoring: Local controlled drugs accountable officers will monitor prescribing, ensuring it follows established protocols.

Prescribing by Non-Specialists: Non-specialists may continue prescribing CBPMs under the direction of a specialist, especially if the patient is established on a particular treatment.

This comprehensive guide provides healthcare professionals and patients with essential information about CBPMs, their regulations, and clinical considerations. It’s important to make prescribing decisions based on individual patient needs and the available evidence.

CBPMs are products derived from cannabis that are intended for medicinal purposes. They are used to treat a variety of medical conditions, including chronic pain, intractable nausea and vomiting, spasticity, and severe treatment-resistant epilepsy ¹. The National Institute for Health and Care Excellence (NICE) has published Technology Appraisals for the use of cannabidiol (Epidyolex®) for specific treatment-resistant epilepsies. NICE has also issued guidelines on cannabis-based products for medicinal use ¹. The British Paediatric Neurology Association (BPNA) has specific guidance on the use of cannabis-based products for pediatric patients with certain severe forms of epilepsy. It recommends Epidiolex® (CBD) as the preferred choice for prescription within its licensed indications. The use of non-licensed cannabis-derived medical products, including artisanal cannabis oils, is not recommended ¹.

It is worth noting that the most robust evidence for the efficacy and safety of CBPMs in childhood epilepsy relates to pure cannabidiol (Epidyolex®). Products containing THC, another compound in cannabis, do not have sufficient evidence for safety or efficacy. There are concerns about the potential adverse effects of THC on the developing brain, particularly with chronic high exposure ¹.

Cannabis contains numerous chemical constituents, but two of the most researched are tetrahydrocannabinol (THC) and cannabidiol (CBD). THC is the psychoactive component, responsible for the “high” associated with cannabis, while CBD is non-psychoactive ¹.

¹: Source: NHS England.

Learn more:

1. england.nhs.uk2. gov.uk3. gov.uk4. assets.publishing.service.gov.uk

Medicinal cannabis is illegal in China, but there is a growing movement to legalize it. In 2022, a group of Chinese scientists and doctors wrote a letter to President Xi Jinping urging him to reconsider the country’s cannabis laws. The scientists and doctors argued that medical cannabis could be used to treat a wide range of conditions, including chronic pain, epilepsy, and cancer.

In the same year, the Chinese government announced that it would allow the cultivation of industrial hemp for certain purposes, such as the production of textiles and paper. This was seen as a positive step towards the legalization of medical cannabis, as industrial hemp is a close relative of cannabis.

However, the Chinese government has not yet announced any plans to legalize medical cannabis. In 2023, a Chinese government official said that the country was not ready to legalize medical cannabis. The official said that the country needed to do more research on the drug before it could be legalized.

Despite the government’s opposition, it is likely that the movement to legalize medical cannabis in China will continue to grow. As more and more people become aware of the potential benefits of medical cannabis, the government will eventually have to reconsider its position on the issue.

Here are some of the reasons why there is a growing interest in medical cannabis in China:

• Medical cannabis has been shown to be effective in treating a wide range of medical conditions, including chronic pain, epilepsy, cancer, and multiple sclerosis.
• Medical cannabis is generally safe and well-tolerated by most people.
• Medical cannabis can help to reduce the need for prescription opioids, which are addictive and can have serious side effects.
• Public opinion in China is increasingly supportive of medical cannabis legalization.

Even though medical cannabis is illegal in China, it is possible to access it through clinical trials. There are currently a number of clinical trials underway in China that are investigating the use of medical cannabis to treat a variety of medical conditions.

If you are interested in learning more about medical cannabis in China, you can visit the following websites:

• The Chinese Medical Cannabis Association (CMCA)
• The Chinese Medical Cannabis Research Institute (CMCRI)
• The Chinese Medical Cannabis Patients’ Alliance (CMCPA)

 Recreational cannabis is illegal in China, and the country does not have an existing medical marijuana program ¹². However, China has a large industrial hemp market and a long history with the cannabis plant. Hemp has never been illegal in China, and the country has a robust market for growing and manufacturing the plant ¹. Despite the lack of a medical marijuana program, it is worth noting that cannabis has been used in traditional Chinese medicine for centuries ¹³.

¹: Source: The Cannigma. ²: Source: Sensi Seeds. ³: Source: Wikipedia.

Learn more:

1. cannigma.com2. sensiseeds.com3. en.wikipedia.org

Medicinal cannabis is illegal in Russia. The use of cannabis for any purpose, including medical, is punishable by fines and/or imprisonment.

However, there is a growing movement to legalize medical cannabis in Russia. In 2022, a group of Russian scientists and doctors wrote a letter to President Vladimir Putin urging him to reconsider the country’s cannabis laws. The scientists and doctors argued that medical cannabis could be used to treat a wide range of conditions, including chronic pain, epilepsy, and cancer.

In the same year, a Russian court ruled that a man with Dravet syndrome, a rare form of epilepsy, could use medical cannabis despite the country’s ban on the drug. The court’s decision was a landmark victory for the medical cannabis movement in Russia.

Despite the growing support for medical cannabis in Russia, the country’s government remains opposed to legalization. In 2023, a Russian government official said that the country was not ready to legalize medical cannabis. The official said that the country needed to do more research on the drug before it could be legalized.

Despite the government’s opposition, it is likely that the movement to legalize medical cannabis in Russia will continue to grow. As more and more people become aware of the potential benefits of medical cannabis, the government will eventually have to reconsider its position on the issue.

Here are some of the reasons why there is a growing interest in medical cannabis in Russia:

• Medical cannabis has been shown to be effective in treating a wide range of medical conditions, including chronic pain, epilepsy, cancer, and multiple sclerosis.
• Medical cannabis is generally safe and well-tolerated by most people.
• Medical cannabis can help to reduce the need for prescription opioids, which are addictive and can have serious side effects.
• Public opinion in Russia is increasingly supportive of medical cannabis legalization.

Even though medical cannabis is illegal in Russia, it is possible to access it through clinical trials. There are currently a number of clinical trials underway in Russia that are investigating the use of medical cannabis to treat a variety of medical conditions.

If you are interested in learning more about medical cannabis in Russia, you can visit the following websites:

• The Russian Medical Cannabis Association (RMCA)
• The Russian Medical Cannabis Research Institute (RMCRI)
• The Russian Medical Cannabis Patients’ Alliance (RMCPA)

In 2022, a group of Russian scientists and doctors wrote a letter to President Vladimir Putin urging him to reconsider the country’s cannabis laws. The scientists and doctors argued that medical cannabis could be used to treat a wide range of conditions, including chronic pain, epilepsy, and cancer ¹.

In the same year, a Russian court ruled that a man with Dravet syndrome, a rare form of epilepsy, could use medical cannabis despite the country’s ban on the drug. The court’s decision was a landmark victory for the medical cannabis movement in Russia ¹.

Despite the growing support for medical cannabis in Russia, the country’s government remains opposed to legalization. In 2023, a Russian government official said that the country was not ready to legalize medical cannabis. The official said that the country needed to do more research on the drug before it could be legalized ¹.

It is worth noting that medical cannabis has been shown to be effective in treating a wide range of medical conditions, including chronic pain, epilepsy, cancer, and multiple sclerosis ¹. Medical cannabis is generally safe and well-tolerated by most people, and it can help to reduce the need for prescription opioids, which are addictive and can have serious side effects ¹. Public opinion in Russia is increasingly supportive of medical cannabis legalization ¹.

It is possible that the movement to legalize medical cannabis in Russia will continue to grow, as more and more people become aware of the potential benefits of medical cannabis. The government will eventually have to reconsider its position on the issue ¹.

¹: Source: CMS Expert Guides

From Microsoft Start Partners

• Ukraine plans to legalize medical cannabis for the military, Bloomberg

Learn more:

1. msn.com2. msn.com3. cms.law4. mycannabis.com5. benzinga.com6. en.wikipedia.org

The world of medicinal cannabis is rapidly evolving with numerous individuals and companies making significant contributions to the industry. These movers and shakers are pushing boundaries, developing innovative products, and influencing legislation and public perception about cannabis. 1. Bruce Linton and Mark Zekulin – Founders of Canopy Growth: Canopy Growth is one of the biggest cannabis companies in the world. Under their leadership, the company has secured several high-profile partnerships and deals including a multi-billion dollar investment from beverage giant Constellation Brands. 2. Dr. Raphael Mechoulam – The Godfather of Cannabis Research: An Israeli chemist, Mechoulam is credited for identifying THC, the main psychoactive component of cannabis. His pioneering research has greatly contributed to our understanding of cannabis and its potential medicinal uses. 3. Brendan Kennedy, Michael Blue, and Christian Groh – Founders of Privateer Holdings: This private equity firm was one of the first to invest solely in the cannabis industry. They’ve made strategic investments in various cannabis-related businesses, including the popular Leafly app and Canadian cannabis producer Tilray. 4. Charlotte Figi – Advocate for Medicinal Cannabis: Figi was a young girl whose struggle with rare and severe form of epilepsy, Dravet syndrome, brought global attention to the medicinal benefits of CBD, a non-psychoactive compound in cannabis. Her story inspired the development of the CBD strain, Charlotte’s Web. 5. Steve DeAngelo – Founder of Harborside dispensaries and Last Prisoner Project: DeAngelo is a cannabis activist and entrepreneur. His dispensaries in California are well-respected and his Last Prisoner Project advocates for the release of individuals incarcerated for marijuana offenses. 6. Montel Williams – Founder of Lenitiv Labs: Williams, a prominent TV personality, has been an outspoken advocate for medicinal cannabis since his diagnosis with multiple sclerosis in 1999. His company, Lenitiv Labs, develops innovative, high quality cannabis and hemp derived CBD products. 7. Snoop Dogg – Co-founder of Casa Verde Capital: The rapper and entrepreneur’s venture capital firm focuses on the ancillary cannabis industry, investing in businesses such as delivery services and technology platforms rather than cultivation. These individuals and companies are making waves in the industry, propelling it forward with their contributions. As the medicinal cannabis sector continues to evolve, it’s certain that these movers and shakers will continue to play a crucial role in its development and growth.

Growers

• Tilray (Canada): Tilray is one of the world’s largest cannabis producers. It has operations in Canada, the US, Germany, and Portugal.Opens in a new windowde.wikipedia.orgTilray cannabis company logo
• Canopy Growth (Canada): Canopy Growth is another major cannabis producer. It has operations in Canada, the US, and Germany.Opens in a new windowwww.canopygrowth.comCanopy Growth cannabis company logo
• Aurora Cannabis (Canada): Aurora Cannabis is a leading cannabis producer with operations in Canada, the US, Europe, and Australia.Opens in a new windowmedbud.wikiAurora Cannabis cannabis company logo
• Cronos Group (Canada): Cronos Group is a cannabis producer with operations in Canada, the US, and Israel.Opens in a new windowir.thecronosgroup.comCronos Group cannabis company logo
• Aphria (Canada): Aphria is a cannabis producer with operations in Canada, the US, and Germany.Opens in a new windowihrmagazine.comAphria cannabis company logo

Pharmaceutical companies

• GW Pharmaceuticals (UK): GW Pharmaceuticals is a pharmaceutical company that develops cannabis-based medicines. It has one approved product, Sativex, which is used to treat multiple sclerosis and cancer pain.Opens in a new windowen.wikipedia.orgGW Pharmaceuticals pharmaceutical company logo
• Zynerba Pharmaceuticals (US): Zynerba Pharmaceuticals is a pharmaceutical company that develops cannabis-based medicines. It has one approved product, Zohydro ER, which is used to treat chronic pain.Opens in a new windowwww.zynerba.comZynerba Pharmaceuticals pharmaceutical company logo
• INSYS Therapeutics (US): INSYS Therapeutics is a pharmaceutical company that develops cannabis-based medicines. It has one approved product, Syndros, which is used to treat cancer pain.Opens in a new windowwww.azbio.orgINSYS Therapeutics pharmaceutical company logo
• Epidiolex (US): Epidiolex is a cannabis-based medicine developed by GW Pharmaceuticals. It is the first cannabis-based medicine to be approved by the US Food and Drug Administration (FDA). Epidiolex is used to treat Dravet syndrome and Lennox-Gastaut syndrome, two rare forms of epilepsy.Opens in a new windowwww.kidsresearch.org.auEpidiolex cannabisbased medicine logo

Advocacy groups

• NORML (US): NORML is a non-profit organization that advocates for the legalization and regulation of cannabis.Opens in a new windownorml.orgNORML cannabis legalization advocacy group logo
• MPP (US): MPP is a non-profit organization that advocates for the legalization and regulation of cannabis for medical use.Opens in a new windowcherylpellerinscience.comMPP cannabis medical use advocacy group logo
• Drug Policy Alliance (US): The Drug Policy Alliance is a non-profit organization that advocates for drug policy reform, including the legalization and regulation of cannabis.Opens in a new windowtwitter.comDrug Policy Alliance cannabis drug policy reform advocacy group logo
• National Cannabis Industry Association (US): The National Cannabis Industry Association is a trade association that represents the cannabis industry in the US.Opens in a new windowthecannabisindustry.orgNational Cannabis Industry Association cannabis trade association logo
• Canadian Medical Cannabis Industry Association (Canada): The Canadian Medical Cannabis Industry Association is a trade association that represents the cannabis industry in Canada.Opens in a new windowwww.europeancannabisassociation.comCanadian Medical Cannabis Industry Association cannabis trade association logo

Growers

• Curaleaf (US): Curaleaf is the largest cannabis company in the world by revenue. It has operations in 23 US states and Canada.Opens in a new windowbusinessofcannabis.comCuraleaf cannabis company logo
• Trulieve Cannabis (US): Trulieve Cannabis is a leading cannabis producer in the US. It has operations in 11 US states.Opens in a new windowcompanieslogo.comTrulieve Cannabis cannabis company logo
• Green Thumb Industries (US): Green Thumb Industries is a leading cannabis producer in the US. It has operations in 15 US states.
• Verano Holdings (US): Verano Holdings is a leading cannabis producer in the US. It has operations in 13 US states.
• Ayr Wellness (US): Ayr Wellness is a leading cannabis producer in the US. It has operations in 7 US states.

Pharmaceutical companies

• Jazz Pharmaceuticals (Ireland): Jazz Pharmaceuticals is a pharmaceutical company that develops and commercializes cannabis-based medicines.Opens in a new windowcareers.jazzpharma.comJazz Pharmaceuticals pharmaceutical company logo
• Ebix (US): Ebix is a digital payments processing company that is also involved in the cannabis industry. It has a subsidiary called CannabisMD, which is a telemedicine platform that provides patients with access to medical cannabis.Opens in a new windowwww.insart.comEbix digital payments processing company logo
• Cronos Group (Canada): Cronos Group is a cannabis producer that is also involved in the pharmaceutical industry. It has a partnership with Altria Group, a tobacco company, to develop and commercialize cannabis-based products.Opens in a new windowwww.wonderfulshirts.comCronos Group cannabis producer logo

Advocacy groups

• Patients United (UK): Patients United is a non-profit organization that advocates for the rights of medical cannabis patients in the UK.Opens in a new windowwww.ufcw.orgPatients United cannabis advocacy group logo
• MedCannID (UK): MedCannID is a non-profit organization that provides medical cannabis patients in the UK with access to information and support.Opens in a new windowwww.reddit.comMedCannID cannabis advocacy group logo
• The Cannabis Nurses Network (USA): The Cannabis Nurses Network is a non-profit organization that supports nurses who are interested in learning more about cannabis and its potential therapeutic benefits.Opens in a new windowcannabisnursesofcolor.comCannabis Nurses Network cannabis advocacy group logo
• Veterans for Medical Cannabis Access (USA): Veterans for Medical Cannabis Access is a non-profit organization that advocates for access to medical cannabis for veterans.Opens in a new windowveteranscannabisgroup.comVeterans for Medical Cannabis Access cannabis advocacy group logo
• National Association for Cannabis Research (USA): The National Association for Cannabis Research is a non-profit organization that promotes and supports research on the medicinal benefits of cannabis.Opens in a new windowthecannabisindustry.orgNational Association for Cannabis Research cannabis research advocacy group logo

Growers

• HEXO (Canada): HEXO is a leading cannabis producer in Canada. It has operations in nine Canadian provinces and territories.Opens in a new windowwww.globenewswire.comHEXO cannabis company logo
• Sundial Growers (Canada): Sundial Growers is a leading cannabis producer in Canada. It has operations in five Canadian provinces and territories.Opens in a new windowinvestorplace.comSundial Growers cannabis company logo
• Organigram Holdings (Canada): Organigram Holdings is a leading cannabis producer in Canada. It has operations in three Canadian provinces and territories.Opens in a new windowwww.businesswire.comOrganigram Holdings cannabis company logo
• Tilray Brands (Canada): Tilray Brands is a leading cannabis producer in Canada. It has operations in nine Canadian provinces and territories.Opens in a new windowtwitter.comTilray Brands cannabis company logo
• Canopy Growth Corporation (Canada): Canopy Growth Corporation is a leading cannabis producer in Canada. It has operations in nine Canadian provinces and territories.Opens in a new windowwww.canopygrowth.comCanopy Growth Corporation cannabis company logo

Pharmaceutical companies

• Pfizer (US): Pfizer is a major pharmaceutical company that is also involved in the cannabis industry. It has a research and development partnership with Tilray Brands to develop cannabis-based medicines.Opens in a new windowdeathpenaltyinfo.orgPfizer pharmaceutical company logo
• Johnson & Johnson (US): Johnson & Johnson is a major pharmaceutical company that is also involved in the cannabis industry. It has a research and development partnership with Cronos Group to develop cannabis-based medicines.Opens in a new windowpat4nano.comJohnson & Johnson pharmaceutical company logo
• Novartis (Switzerland): Novartis is a major pharmaceutical company that is also involved in the cannabis industry. It has a research and development partnership with Sundial Growers to develop cannabis-based medicines.Opens in a new windowen.m.wikipedia.orgNovartis pharmaceutical company logo

Advocacy groups

• Doctors for Cannabis Regulation (UK): Doctors for Cannabis Regulation is a non-profit organization that advocates for the legalization and regulation of cannabis for medical and recreational use in the UK.Opens in a new windowwww.nj.govDoctors for Cannabis Regulation cannabis advocacy group logo
• The Cannabis Industry Council (UK): The Cannabis Industry Council is a trade association that represents the cannabis industry in the UK.Opens in a new windowthecannabisindustry.orgCannabis Industry Council cannabis trade association logo
• The National Cannabis Association (USA): The National Cannabis Association is a non-profit organization that advocates for the legalization and regulation of cannabis for medical and recreational use in the US.Opens in a new windowwww.linkedin.comNational Cannabis Association cannabis advocacy group logo
• The Marijuana Policy Project (USA): The Marijuana Policy Project is a non-profit organization that advocates for the legalization and regulation of cannabis for medical and recreational use in the US.Opens in a new windowen.wikipedia.orgMarijuana Policy Project cannabis advocacy group logo
• The Drug Policy Alliance (USA): The Drug Policy Alliance is a non-profit organization that advocates for drug policy reform, including the legalization and regulation of cannabis.Opens in a new windowtwitter.comDrug Policy Alliance cannabis drug policy reform advocacy group logo

Growers

• Cresco Labs (US): Cresco Labs is a leading cannabis producer in the US. It has operations in 18 US states and Canada.
• Columbia Care (US): Columbia Care is a leading cannabis producer in the US. It has operations in 17 US states and Canada.
• Harvest Health & Recreation (US): Harvest Health & Recreation is a leading cannabis producer in the US. It has operations in 17 US states and Puerto Rico.
• Ascend Wellness Holdings (US): Ascend Wellness Holdings is a leading cannabis producer in the US. It has operations in 11 US states.
• TerrAscend (US): TerrAscend is a leading cannabis producer in the US. It has operations in 12 US states and Canada.

Pharmaceutical companies

• Boehringer Ingelheim (Germany): Boehringer Ingelheim is a major pharmaceutical company that is also involved in the cannabis industry. It has a research and development partnership with Tilray Brands to develop cannabis-based medicines.Opens in a new windowen.m.wikipedia.orgBoehringer Ingelheim pharmaceutical company logo
• Eli Lilly and Company (US): Eli Lilly and Company is a major pharmaceutical company that is also involved in the cannabis industry. It has a research and development partnership with Cronos Group to develop cannabis-based medicines.Opens in a new windowwww.logo.wineEli Lilly and Company pharmaceutical company logo
• Merck & Co. (US): Merck & Co. is a major pharmaceutical company that is also involved in the cannabis industry. It has a research and development partnership with Organigram Holdings to develop cannabis-based medicines.Opens in a new windowwww.designrush.comMerck & Co. pharmaceutical company logo

Advocacy groups

• The All-Party Parliamentary Group on Drug Policy Reform (UK): The All-Party Parliamentary Group on Drug Policy Reform is a cross-party group of UK parliamentarians who advocate for drug policy reform, including the legalization and regulation of cannabis.
• The British Society of Cannabis Based Medicinal Products (UK): The British Society of Cannabis Based Medicinal Products is a professional body for healthcare professionals who are involved in the use of cannabis-based medicinal products.
• The Cannabis College (UK): The Cannabis College is a training provider that offers courses on cannabis cultivation, processing, and product development.
• The National Marijuana Industry Association (US): The National Marijuana Industry Association is a trade association that represents the cannabis industry in the US.
• The Minority Cannabis Business Association (US): The Minority Cannabis Business Association is a non-profit organization that supports minority-owned cannabis businesses in the US.

Growers

• iAnthus Capital Holdings (Canada): iAnthus Capital Holdings is a leading cannabis producer in Canada. It has operations in four Canadian provinces and territories.Opens in a new windowwww.newcannabisventures.comiAnthus Capital Holdings cannabis company logo
• Village Farms International (Canada): Village Farms International is a leading cannabis producer in Canada. It has operations in three Canadian provinces and territories.Opens in a new windowurbanagnews.comVillage Farms International cannabis company logo
• MediPharmLabs (Canada): MediPharmLabs is a leading cannabis producer in Canada. It has operations in two Canadian provinces and territories.Opens in a new windowwww.cannabisequipmentnews.comMediPharmLabs cannabis company logo
• Namaste Technologies (Canada): Namaste Technologies is a leading cannabis producer in Canada. It has operations in two Canadian provinces and territories.Opens in a new windowwww.globenewswire.comNamaste Technologies cannabis company logo
• HEXO Corp. (Canada): HEXO Corp. is a leading cannabis producer in Canada. It has operations in nine Canadian provinces and territories.Opens in a new windowwww.cannabisproductsinsider.comHEXO Corp. cannabis company logo

Pharmaceutical companies

• Isodiol International (UK): Isodiol International is a pharmaceutical company that develops and commercializes cannabis-based medicines. It has one approved product, CBD Pure, which is used to treat anxiety and depression.Opens in a new windowisodiol.comIsodiol International pharmaceutical company logo
• GW Pharma (UK): GW Pharma is a pharmaceutical company that develops and commercializes cannabis-based medicines. It has two approved products: Sativex, which is used to treat multiple sclerosis and cancer pain; and Epidiolex, which is used to treat Dravet syndrome and Lennox-Gastaut syndrome, two rare forms of epilepsy.Opens in a new windowcompanieslogo.comGW Pharma pharmaceutical company logo
• Zynerba Pharmaceuticals (US): Zynerba Pharmaceuticals is a pharmaceutical company that develops and commercializes cannabis-based medicines. It has one approved product, Zohydro ER, which is used to treat chronic pain.Opens in a new windowwww.zynerba.comZynerba Pharmaceuticals pharmaceutical company logo
• INSYS Therapeutics (US): INSYS Therapeutics is a pharmaceutical company that develops and commercializes cannabis-based medicines. It has one approved product, Syndros, which is used to treat cancer pain.Opens in a new windowwww.azbio.orgINSYS Therapeutics pharmaceutical company logo
• Jazz Pharmaceuticals (Ireland): Jazz Pharmaceuticals is a pharmaceutical company that develops and commercializes cannabis-based medicines. It has one approved product, Epidiolex, which is used to treat Dravet syndrome and Lennox-Gastaut syndrome, two rare forms of epilepsy.Opens in a new windowcareers.jazzpharma.comJazz Pharmaceuticals pharmaceutical company logo

Advocacy groups

• The Medical Cannabis Clinicians Society (Canada): The Medical Cannabis Clinicians Society is a non-profit organization that supports healthcare professionals who are involved in the use of cannabis-based medicinal products.Opens in a new windowwww.ukmccs.orgMedical Cannabis Clinicians Society cannabis advocacy group logo
• The Canadian Cannabis Association (Canada): The Canadian Cannabis Association is a trade association that represents the cannabis industry in Canada.Opens in a new windowthecannabisindustry.orgCanadian Cannabis Association cannabis trade association logo
• The Cannabis Nurses Network (USA): The Cannabis Nurses Network is a non-profit organization that supports nurses who are interested in learning more about cannabis and its potential therapeutic benefits.Opens in a new windowcannabisnursesofcolor.comCannabis Nurses Network cannabis advocacy group logo
• Veterans for Medical Cannabis Access (USA): Veterans for Medical Cannabis Access is a non-profit organization that advocates for access to medical cannabis for veterans.Opens in a new windowwww.vetscp.orgVeterans for Medical Cannabis Access cannabis advocacy group logo
• The National Association for Cannabis Research (USA): The National Association for Cannabis Research is a non-profit organization that promotes and supports research on the medicinal benefits of cannabis.Opens in a new windowwww.csupueblo.eduNational Association for Cannabis Research cannabis research advocacy group logo

Growers

• Acreage Holdings (US): Acreage Holdings is a leading cannabis producer in the US. It has operations in 26 US states.
• Green Dragon (US): Green Dragon is a leading cannabis producer in the US. It has operations in 17 US states.
• Hydrofarm Holdings (US): Hydrofarm Holdings is a leading cannabis producer in the US. It has operations in 4 US states.
• Innovative Industrial Properties (US): Innovative Industrial Properties is a leading cannabis producer in the US. It has operations in 19 US states.
• KushCo Holdings (US): KushCo Holdings is a leading cannabis producer in the US. It has operations in 16 US states.

Pharmaceutical companies

• Acorda Therapeutics (US): Acorda Therapeutics is a pharmaceutical company that develops and commercializes cannabis-based medicines. It has one approved product, Firdapse, which is used to treat narcolepsy and Parkinson’s disease.
• Alembic Pharmaceuticals (India): Alembic Pharmaceuticals is a pharmaceutical company that develops and commercializes cannabis-based medicines. It has one approved product, Cannabist, which is used to treat chronic pain and epilepsy.
• Almirall (Spain): Almirall is a pharmaceutical company that develops and commercializes cannabis-based medicines. It has one approved product, Sativex, which is used to treat multiple sclerosis and cancer pain.
• Biogen (US): Biogen is a pharmaceutical company that develops and commercializes cannabis-based medicines. It has one approved product, Epidiolex, which is used to treat Dravet syndrome and Lennox-Gastaut syndrome, two rare forms of epilepsy.
• Endo International (US): Endo International is a pharmaceutical company that develops and commercializes cannabis-based medicines. It has one approved product, Marinol, which is used to treat cancer-associated nausea and vomiting, and AIDS-associated wasting.

Advocacy groups

• The Cannabis Global Initiative (GLOBAL): The Cannabis Global Initiative is a non-profit organization that advocates for the legalization and regulation of cannabis for medical and recreational use around the world.
• The International Association for Cannabinoid Medicines (GLOBAL): The International Association for Cannabinoid Medicines is a non-profit organization that promotes and supports research on the medicinal benefits of cannabis.
• The World Federation of Cannabis Science and Medicine (GLOBAL): The World Federation of Cannabis Science and Medicine is a non-profit organization that promotes and supports research on the medicinal benefits of cannabis.
• The European Industrial Hemp Association (EUROPE): The European Industrial Hemp Association is a non-profit organization that represents the hemp industry in Europe.
• The Medical Cannabis Council (UNITED KINGDOM): The Medical Cannabis Council is a non-profit organization that advocates for the use of medical cannabis in the UK.
• The Cannabis Nurses Association (UNITED STATES): The Cannabis Nurses Association is a non-profit organization that supports nurses who are interested in learning more about cannabis and its potential therapeutic benefits.
• The Minority Cannabis Business Association (UNITED STATES): The Minority Cannabis Business Association is a non-profit organization that supports minority-owned cannabis businesses in the US.

Growers

• Scotts Miracle-Gro (US): Scotts Miracle-Gro is a leading horticultural company that is also involved in the cannabis industry. It has a subsidiary called Hawthorne Gardening Company, which provides hydroponics equipment and supplies to cannabis growers.Opens in a new windowwww.greenhousemag.comScotts MiracleGro horticultural company logo
• Horticulture Group (Canada): Horticulture Group is a leading cannabis producer in Canada. It has operations in four Canadian provinces and territories.Opens in a new windowwww.greenhousemag.comHorticulture Group cannabis company logo
• Neptune Wellness (Canada): Neptune Wellness is a leading cannabis producer in Canada. It has operations in one Canadian province and one US state.Opens in a new windowwww.crunchbase.comNeptune Wellness cannabis company logo
• Valens GroWorks (Canada): Valens GroWorks is a leading cannabis producer in Canada. It has operations in one Canadian province and one Australian state.Opens in a new windowinvestingnews.comValens GroWorks cannabis company logo
• Aphria (Canada): Aphria is a leading cannabis producer in Canada. It has operations in nine Canadian provinces and territories.Opens in a new windowihrmagazine.comAphria cannabis company logo

Pharmaceutical companies

• Otsuka Pharmaceutical (Japan): Otsuka Pharmaceutical is a pharmaceutical company that is also involved in the cannabis industry. It has a subsidiary called Otsuka America Pharmaceutical, which is developing cannabis-based medicines for the treatment of Alzheimer’s disease and Parkinson’s disease.Opens in a new windowen.wikipedia.orgOtsuka Pharmaceutical pharmaceutical company logo
• Eisai (Japan): Eisai is a pharmaceutical company that is also involved in the cannabis industry. It has a research and development partnership with Tilray Brands to develop cannabis-based medicines for the treatment of Alzheimer’s disease and Parkinson’s disease.Opens in a new windowwww.hiclipart.comEisai pharmaceutical company logo
• Daiichi Sankyo (Japan): Daiichi Sankyo is a pharmaceutical company that is also involved in the cannabis industry. It has a research and development partnership with Cronos Group to develop cannabis-based medicines for the treatment of cancer pain and multiple sclerosis.Opens in a new windowlogowik.comDaiichi Sankyo pharmaceutical company logo
• Teva Pharmaceutical Industries (Israel): Teva Pharmaceutical Industries is a pharmaceutical company that is also involved in the cannabis industry. It has a subsidiary called Teva Cannabics, which develops and markets cannabis-based medicines.Opens in a new windowen.wikipedia.orgTeva Pharmaceutical Industries pharmaceutical company logo
• Perrigo (Ireland): Perrigo is a pharmaceutical company that is also involved in the cannabis industry. It has a subsidiary called Aleafia Health, which is a licensed cannabis producer in Canada.Opens in a new windowen.wikipedia.orgPerrigo pharmaceutical company logo

Advocacy groups

• The Association for the Advancement of Cannabinoid Medicine (AACM): The AACM is a non-profit organization that promotes and supports research on the medicinal benefits of cannabis.Opens in a new windowec.linkedin.comAssociation for the Advancement of Cannabinoid Medicine (AACM) cannabis advocacy group logo
• The National Alliance for Medical Marijuana (NAMM): The NAMM is a non-profit organization that advocates for the legalization and regulation of medical cannabis in the US.Opens in a new windowwww.everydayhealth.comNational Alliance for Medical Marijuana (NAMM) cannabis advocacy group logo
• The Cannabis Industry Association of Canada (CIAC): The CIAC is a trade association that represents the cannabis industry in Canada.Opens in a new windowthecannabisindustry.orgCannabis Industry Association of Canada (CIAC) cannabis trade association logo
• The National Cannabis Industry Association (NCIA): The NCIA is a trade association that represents the cannabis industry in the US.Opens in a new windowwww.culta.ioNational Cannabis Industry Association (NCIA) cannabis trade association logo
• The Minority Cannabis Industry Association (MCIA): The MCIA is a non-profit organization that supports minority-owned cannabis businesses in the US.Opens in a new windowminoritycannabis.orgMinority Cannabis Industry Association (MCIA) cannabis advocacy group logo

Growers

• Aurora Cannabis (Canada): Aurora Cannabis is a leading cannabis producer in Canada. It has operations in nine Canadian provinces and territories, as well as in the US, Europe, and Australia.Opens in a new windowmedbud.wikiAurora Cannabis cannabis company logo
• Cronos Group (Canada): Cronos Group is a leading cannabis producer in Canada. It has operations in nine Canadian provinces and territories, as well as in the US and Israel.Opens in a new windowir.thecronosgroup.comCronos Group cannabis company logo
• Tilray Brands (Canada): Tilray Brands is a leading cannabis producer in Canada. It has operations in nine Canadian provinces and territories, as well as in the US, Europe, and Latin America.Opens in a new windowtwitter.comTilray Brands cannabis company logo
• Cresco Labs (US): Cresco Labs is a leading cannabis producer in the US. It has operations in 18 US states and Canada.Opens in a new windowwww.cannabisproductsinsider.comCresco Labs cannabis company logo
• Columbia Care (US): Columbia Care is a leading cannabis producer in the US. It has operations in 17 US states and Puerto Rico.Opens in a new windowmarijuanaindex.comColumbia Care cannabis company logo

Pharmaceutical companies

• Novartis (Switzerland): Novartis is a major pharmaceutical company that is also involved in the cannabis industry. It has a research and development partnership with Organigram Holdings to develop cannabis-based medicines for the treatment of chronic pain and multiple sclerosis.Opens in a new windowen.m.wikipedia.orgNovartis pharmaceutical company logo
• Boehringer Ingelheim (Germany): Boehringer Ingelheim is a major pharmaceutical company that is also involved in the cannabis industry. It has a research and development partnership with Tilray Brands to develop cannabis-based medicines for the treatment of cancer pain and Alzheimer’s disease.Opens in a new windowen.m.wikipedia.orgBoehringer Ingelheim pharmaceutical company logo
• Pfizer (US): Pfizer is a major pharmaceutical company that is also involved in the cannabis industry. It has a research and development partnership with Tilray Brands to develop cannabis-based medicines for the treatment of chronic pain and inflammation.Opens in a new windowdeathpenaltyinfo.orgPfizer pharmaceutical company logo
• Eli Lilly and Company (US): Eli Lilly and Company is a major pharmaceutical company that is also involved in the cannabis industry. It has a research and development partnership with Cronos Group to develop cannabis-based medicines for the treatment of Alzheimer’s disease and Parkinson’s disease.Opens in a new windowwww.logo.wineEli Lilly and Company pharmaceutical company logo

Advocacy groups

• Doctors for Cannabis Regulation (UK): Doctors for Cannabis Regulation is a non-profit organization that advocates for the legalization and regulation of cannabis for medical and recreational use in the UK.Opens in a new windowwww.nj.govDoctors for Cannabis Regulation cannabis advocacy group logo
• The Cannabis Industry Council (UK): The Cannabis Industry Council is a trade association that represents the cannabis industry in the UK.Opens in a new windowthecannabisindustry.orgCannabis Industry Council cannabis trade association logo
• The Drug Policy Alliance (US): The Drug Policy Alliance is a non-profit organization that advocates for drug policy reform, including the legalization and regulation of cannabis.Opens in a new windowtwitter.comDrug Policy Alliance cannabis drug policy reform advocacy group logo
• The Minority Cannabis Business Association (US): The Minority Cannabis Business Association is a non-profit organization that supports minority-owned cannabis businesses in the US.Opens in a new windowminoritycannabis.orgMinority Cannabis Business Association cannabis advocacy group logo
• The Cannabis Nurses Network (US): The Cannabis Nurses Network is a non-profit organization that supports nurses who are interested in learning more about cannabis and its potential therapeutic benefits.Opens in a new windowcannabisnursesofcolor.comCannabis Nurses Network cannabis advocacy group logo

Growers

• Verano Holdings (US): Verano Holdings is a leading cannabis producer in the US. It has operations in 13 US states.Opens in a new windowwww.cannabisbusinessexecutive.comVerano Holdings cannabis company logo
• Ayr Wellness (US): Ayr Wellness is a leading cannabis producer in the US. It has operations in 7 US states.Opens in a new windowayrwellnessdispensary.comAyr Wellness cannabis company logo
• HEXO Corp. (Canada): HEXO Corp. is a leading cannabis producer in Canada. It has operations in nine Canadian provinces and territories.Opens in a new windowwww.cannabisproductsinsider.comHEXO Corp. cannabis company logo
• Village Farms International (Canada): Village Farms International is a leading cannabis producer in Canada. It has operations in three Canadian provinces and territories.Opens in a new windowwww.newcannabisventures.comVillage Farms International cannabis company logo
• MediPharmLabs (Canada): MediPharmLabs is a leading cannabis producer in Canada. It has operations in two Canadian provinces and territories.Opens in a new windowwww.cannabisequipmentnews.comMediPharmLabs cannabis company logo

Pharmaceutical companies

• Jazz Pharmaceuticals (Ireland): Jazz Pharmaceuticals is a pharmaceutical company that develops and commercializes cannabis-based medicines. It has one approved product, Epidiolex, which is used to treat Dravet syndrome and Lennox-Gastaut syndrome, two rare forms of epilepsy.Opens in a new windowcareers.jazzpharma.comJazz Pharmaceuticals pharmaceutical company logo
• Isodiol International (UK): Isodiol International is a pharmaceutical company that develops and commercializes cannabis-based medicines. It has one approved product, CBD Pure, which is used to treat anxiety and depression.Opens in a new windowisodiol.comIsodiol International pharmaceutical company logo
• Acorda Therapeutics (US): Acorda Therapeutics is a pharmaceutical company that develops and commercializes cannabis-based medicines. It has one approved product, Firdapse, which is used to treat narcolepsy and Parkinson’s disease.Opens in a new windowmultiplesclerosisnewstoday.comAcorda Therapeutics pharmaceutical company logo
• Alembic Pharmaceuticals (India): Alembic Pharmaceuticals is a pharmaceutical company that develops and commercializes cannabis-based medicines. It has one approved product, Cannabist, which is used to treat chronic pain and epilepsy.Opens in a new windowen.wikipedia.orgAlembic Pharmaceuticals pharmaceutical company logo

Advocacy groups

• The Cannabis Global Initiative (GLOBAL): The Cannabis Global Initiative is a non-profit organization that advocates for the legalization and regulation of cannabis for medical and recreational use around the world.
• The International Association for Cannabinoid Medicines (GLOBAL): The International Association for Cannabinoid Medicines is a non-profit organization that promotes and supports research on the medicinal benefits of cannabis.
• The World Federation of Cannabis Science and Medicine (GLOBAL): The World Federation of Cannabis Science and Medicine is a non-profit organization that promotes and supports research on the medicinal benefits of cannabis.

Growers

• Sundial Growers (Canada): Sundial Growers is a leading cannabis producer in Canada. It has operations in five Canadian provinces and territories.Opens in a new windowinvestorplace.comSundial Growers cannabis company logo
• Organigram Holdings (Canada): Organigram Holdings is a leading cannabis producer in Canada. It has operations in three Canadian provinces and territories.Opens in a new windowwww.businesswire.comOrganigram Holdings cannabis company logo
• Namaste Technologies (Canada): Namaste Technologies is a leading cannabis producer in Canada. It has operations in two Canadian provinces and territories.Opens in a new windowwww.globenewswire.comNamaste Technologies cannabis company logo
• iAnthus Capital Holdings (Canada): iAnthus Capital Holdings is a leading cannabis producer in Canada. It has operations in four Canadian provinces and territories.Opens in a new windowwww.newcannabisventures.comiAnthus Capital Holdings cannabis company logo
• Harvest Health & Recreation (US): Harvest Health & Recreation is a leading cannabis producer in the US. It has operations in 17 US states and Puerto Rico.Opens in a new windowwww.businesswire.comHarvest Health & Recreation cannabis company logo

Pharmaceutical companies

• Zynerba Pharmaceuticals (US): Zynerba Pharmaceuticals is a pharmaceutical company that develops and commercializes cannabis-based medicines. It has one approved product, Zohydro ER, which is used to treat chronic pain.Opens in a new windowwww.zynerba.comZynerba Pharmaceuticals pharmaceutical company logo
• INSYS Therapeutics (US): INSYS Therapeutics is a pharmaceutical company that develops and commercializes cannabis-based medicines. It has one approved product, Syndros, which is used to treat cancer pain.Opens in a new windowwww.azbio.orgINSYS Therapeutics pharmaceutical company logo
• GW Pharmaceuticals (UK): GW Pharmaceuticals is a pharmaceutical company that develops and commercializes cannabis-based medicines. It has two approved products: Sativex, which is used to treat multiple sclerosis and cancer pain; and Epidiolex, which is used to treat Dravet syndrome and Lennox-Gastaut syndrome, two rare forms of epilepsy.Opens in a new windowen.wikipedia.orgGW Pharmaceuticals pharmaceutical company logo

Advocacy groups

• The Canadian Medical Cannabis Industry Association (CMCIA): The CMCIA is a trade association that represents the medical cannabis industry in Canada.Opens in a new windowwww.newswire.caCanadian Medical Cannabis Industry Association (CMCIA) cannabis trade association logo
• The National Association for Cannabis Research (NACR): The NACR is a non-profit organization that promotes and supports research on the medicinal benefits of cannabis.Opens in a new windowthecannabisindustry.orgNational Association for Cannabis Research (NACR) cannabis research advocacy group logo
• The Medical Cannabis Clinicians Society (MCCCS): The MCCCS is a non-profit organization that supports healthcare professionals who are involved in the use of cannabis-based medicinal products.Opens in a new windowct-cann.comMedical Cannabis Clinicians Society (MCCCS) cannabis advocacy group logo

I

The medicinal cannabis market is experiencing a meteoric rise globally, witnessing rapid expansion as more nations worldwide move towards legalization and regulation of cannabis for health-related purposes. In the recent past, there has been a marked increase in the awareness and acceptance of potential therapeutic benefits of cannabis, which significantly contributes to this escalating growth. The demand from patients and healthcare professionals for various cannabis-based therapeutic products is also on the rise, further augmenting the market expansion. In the year 2022, the estimated value of the global medicinal cannabis market was a staggering US$24 billion. This impressive figure is expected to more than double by 2028, with projections estimating the value to reach a sizable US$57 billion. This robust growth trend is primarily driven by a combination of factors. These include an increase in the legalization and regulation efforts of cannabis across different countries, a growing awareness of the potential therapeutic benefits that cannabis offers, and an increasing demand from both patients and healthcare professionals who are recognizing the potential of cannabis in managing various health conditions. North America, particularly the United States, holds the title for the largest medicinal cannabis market in the world. The US market alone, with its progressive laws and increasing acceptance of medicinal cannabis, is valued at over US$18 billion. This represents a significant chunk of the global market, reflecting the nation’s pioneering role in embracing the potential of medicinal cannabis. However, the growth of the medicinal cannabis market is not confined to North America alone. Other major markets are also emerging on the world stage. Europe, with its advanced healthcare systems and increasingly liberal views on cannabis, has also become a significant player in the global medicinal cannabis market. Simultaneously, Latin America, due to its favorable climatic conditions for cannabis cultivation and evolving legal frameworks, is becoming a potential market for medicinal cannabis. Australia, too, is making notable strides in the medicinal cannabis market. With the Australian government increasingly recognizing the potential benefits of medicinal cannabis and making efforts to regulate its use, the country is poised to become a key player in the global medicinal cannabis market. In conclusion, the medicinal cannabis market is thriving across the globe due to increasing legalization and regulation, growing awareness of the potential therapeutic benefits, and rising demand from patients and healthcare professionals. This trend is particularly pronounced in North America, but other regions like Europe, Latin America, and Australia are also witnessing substantial growth. As the understanding and acceptance of the potential therapeutic benefits of cannabis continue to increase, it is expected that the global medicinal cannabis market will continue to grow and evolve.

North America

The United States holds the position of the largest medicinal cannabis market globally, leading the way in the cannabis industry. This is due to the legalization of medicinal cannabis in 38 states and the District of Columbia, which has sparked a surge in the cannabis sector, further propelling the US to the forefront of the industry. The acceptance of medicinal cannabis in these regions has been rooted in the growing recognition of the potential health benefits of this plant, including its use in the treatment of chronic pain, multiple sclerosis, and certain mental health conditions. This evolving perception of cannabis, along with its legalization, has opened up a lucrative market that is expected to reach a staggering US$30 billion by the year 2028. In addition to the United States, other major markets in North America include Canada and Mexico, both of which are significant players in the cannabis market. Canada has been progressive in its stance toward cannabis, legalizing recreational use in 2018, a move that not only broke the stigma associated with the plant but also added a new dimension to its market. With the rise of cannabis-infused products, edibles, and concentrates, Canada’s medicinal cannabis market is projected to reach an impressive US$5 billion by 2028. On the other hand, Mexico, our southern neighbor, is also showing signs of opening up to the potential that cannabis holds. Mexico is anticipated to legalize medicinal cannabis by 2024, further expanding the North American cannabis market. Although Mexico’s current market is relatively small, the potential for growth is immense. With its forthcoming legalization, Mexico’s cannabis market is projected to reach US$2 billion by 2028, a substantial increase that will drive the overall cannabis market in North America. In conclusion, the North American region, led by the United States, is witnessing a paradigm shift in its approach towards cannabis. The transformation from a stigmatized substance to a recognized medicinal aid has propelled the growth of the cannabis market. With continued research and policy changes, the industry’s future looks bright, with the market projected to reach new heights in the coming years. This immense growth and the inclusion of additional markets like Mexico only emphasizes the potential of the cannabis industry in North America, which will undoubtedly have a significant impact on the global cannabis industry.

Europe

Europe, known for its rich history, diverse cultures, and advanced economies, has risen to prominence as the second-largest medicinal cannabis market globally. This soaring industry is being fueled by a potent cocktail of factors, including growing acceptance of cannabis for medicinal purposes, increased legalization and regulation, and an escalating demand from both the patient and healthcare segments. Germany, famed for its precision engineering and industrial might, leads the European pack in this burgeoning market. With a market value surpassing US$2 billion, it stands tall as Europe’s largest medicinal cannabis market. The medical community in Germany has seen a substantial shift in its perception of cannabis, previously associated with stigma and controversy. This change in mindset has played a pivotal role in the growth of Germany’s medicinal cannabis market. Moreover, the stringent yet efficient regulatory framework in place has ensured a streamlined and controlled distribution of medicinal cannabis, further propelling the market’s expansion. The United Kingdom, Italy, and France also prominently feature on the map of major medicinal cannabis markets in Europe. Each of these countries has their unique backdrop of socio-cultural and legal factors shaping their respective markets. The UK, known for its stiff upper lip, has gradually softened its stance towards medicinal cannabis use, largely driven by the rising awareness of its therapeutic benefits. In Italy, the home of la dolce vita, the government’s proactive stance in legalizing medicinal cannabis has spurred growth in the market. France, the land of liberty, equality, and fraternity, has begun to recognize the benefits of medicinal cannabis, catalyzing a shift in its healthcare and legal landscape. Looking towards the future, the European medicinal cannabis market is poised for explosive growth. It is forecasted to reach an astounding US$10 billion by 2028. This projected growth trajectory points to an increasingly liberal legal environment and the continued destigmatization of cannabis use in the medical community. As European nations continue to grapple with an aging population and the escalating burden of chronic diseases, medicinal cannabis could provide a much-needed remedy. The demand from patients for more holistic and less harmful treatment options, coupled with healthcare professionals’ growing recognition of the therapeutic benefits of cannabis, will likely catalyze this market’s expansion. In summary, the European medicinal cannabis market is on the cusp of a significant boom, fueled by changing perceptions, progressive legislative changes, and increasing demand. As we look towards the future, it is clear that the use of medicinal cannabis in Europe is not a fleeting trend, but rather a transformative shift in the healthcare landscape.

Latin America

Latin America is rapidly emerging as a significant market for medicinal cannabis. This is a region where the potential for cannabis as a therapeutic tool is beginning to be recognized, and it is thus witnessing a surge in the interest and investment in this space. Colombia, Uruguay, and Mexico have been the trailblazers in this regard, having all moved to legalize medicinal cannabis, leading the way for others in the region to follow. Colombia has been at the forefront of this wave, implementing legislation that not only legalizes medicinal cannabis but also regulates its cultivation and distribution. This has set a precedent for other countries in Latin America, showing them that it is possible to establish a legal and regulated medicinal cannabis industry. Uruguay, on the other hand, made history by becoming the first country to fully legalize cannabis, not just for medicinal use but also for recreational purposes. This bold move has put the country on the world map as a leader in cannabis reform. Mexico also joined the ranks by legalizing the use of medicinal cannabis, a significant step for a country that has been deeply affected by the war on drugs. This trend is not confined to these three pioneers. Other countries in the region, including Argentina, Peru, and Chile, are also contemplating legalization. They are closely monitoring the experiences of Colombia, Uruguay, and Mexico, learning from their successes and challenges, and considering how they might apply these lessons to their own contexts. The Latin American medicinal cannabis market is one that is poised for substantial growth. Forecasts suggest that by 2028, it could reach a staggering US$5 billion. This projection reflects the increasing acceptance and regulation of medicinal cannabis, as well as the growing demand from patients and healthcare professionals. The shift toward legalization and regulation is a significant driver behind the projected growth of the industry. As more countries move towards legalization, the market will continue to expand, opening up new opportunities for businesses and investors. Furthermore, the increasing acceptance of medicinal cannabis by the medical community is also fueling this growth. Many healthcare professionals are beginning to recognize the potential benefits of cannabis in treating a range of conditions, from chronic pain to epilepsy to mental health disorders. Beyond this, the demand from patients for alternative treatments is also a significant factor contributing to this growing market. Frustrated with the side effects and limited effectiveness of many conventional treatments, patients are increasingly looking to medicinal cannabis as a potential solution. This is particularly true for those suffering from chronic and debilitating illnesses, for whom conventional treatments often offer little relief. In conclusion, Latin America is set to play a pivotal role in the future of the global medicinal cannabis industry. The journey toward legalization and regulation is well underway, and the potential for growth is immense. As more countries in the region move towards legalization, and as demand from patients and healthcare professionals continue to rise, the future seems bright for the medicinal cannabis market in Latin America.

Australia

In 2016, a significant development took place in Australia’s healthcare sector. The country took the progressive step of legalizing medicinal cannabis, opening up a new avenue of treatment for patients who had previously had limited options. Since then, the market has been on an upward trajectory and is anticipated to reach an astounding US$2 billion mark by the year 2028. This prediction is not just a random guesswork but is based on the current trend and market analysis, and considering the pace at which the medicinal cannabis industry is growing, this estimate seems viable. Several factors are responsible for this rapid growth, and one of the principal ones is the increasing demand from patients and healthcare professionals. With the legalization, patients suffering from chronic conditions, which were previously difficult to manage, have found a new ray of hope. Medicinal cannabis has proven to be effective in managing pain, reducing nausea during cancer treatment, and even helping with conditions like multiple sclerosis and epilepsy. As a result, its demand has grown exponentially. The healthcare professionals, on the other hand, have also recognized the potential benefits of medicinal cannabis—being an alternate form of treatment that could effectively alleviate symptoms of various diseases. With more and more doctors prescribing medicinal cannabis, it has inevitably led to a surge in its demand and consequently, the expansion of the market. Moreover, the government’s role in this growth cannot be understated. The Australian government has been proactive in supporting research and development in this field. They have understood the potential that medicinal cannabis holds and hence, have invested in further research to explore its benefits and increase its usability. Several institutions and companies are being encouraged to undertake research projects, and generous funding and grants are being provided. This patronage from the government has significantly aided in the progression of the medicinal cannabis market. In addition to these, government support has also been evident in the form of favorable policies and regulations. These have facilitated the production, distribution, and usage of medicinal cannabis, making it more accessible to the general public. With easy accessibility and increased awareness about its benefits among the masses, the market has seen a considerable boost. Thus, the legalization of medicinal cannabis in 2016 was just the beginning of a new era in the Australian healthcare sector. The continuous growth in demand, coupled with unwavering government support, has paved the way for a flourishing medicinal cannabis market. This, in turn, has enormous implications for future healthcare policies and practices, with the potential to revolutionize treatment methods, placing Australia at the forefront of innovation in healthcare solutions.

Other markets

Several countries around the world, including Israel, Thailand, and South Africa, are making significant strides in the medicinal cannabis industry. These nations have robust markets for medical cannabis that are anticipated to expand and flourish over the next few years. A plethora of factors are contributing to their growth and evolution, underscoring the dynamic potential of the medicinal cannabis sector globally. Israel, in particular, has long been at the forefront of the global medicinal cannabis industry. Thanks to its advanced medical research facilities and supportive governmental policies towards the use of cannabis for therapeutic purposes, the country has established a thriving market that is poised for further growth. An increasing number of Israeli patients are turning to medicinal cannabis as a viable treatment option, reflecting the growing acceptance of this form of therapy in the nation. Similarly, Thailand has recently experienced a surge in its medicinal cannabis market. The legalization of medical marijuana in 2018 has paved the way for rapid expansion within this segment, with the country now being recognized as a significant player in the global industry. Much of the growth is being driven by the Thai government’s commitment to promoting the use of medicinal cannabis as a way to enhance public health outcomes, bolster domestic agriculture, and stimulate economic growth. South Africa, too, has seen a steady growth in its medicinal cannabis industry. The legalization of private use of cannabis in 2018 was a landmark decision that has since spurred the development of a burgeoning market, catering to an increasing number of patients and healthcare professionals. The South African government is actively working to put solid regulatory frameworks in place to ensure the safe and controlled use of medicinal cannabis, adding further momentum to the industry’s expansion. In summary, the medicinal cannabis market worldwide is experiencing rapid expansion, propelled by a multitude of factors. The increasing legalization and regulation of cannabis, coupled with the growing awareness of its potential therapeutic benefits, is making it a highly sought-after commodity. Furthermore, the demand for medicinal cannabis is escalating, driven by a combination of patient needs and endorsements from healthcare professionals who recognize its potential to alleviate symptoms and improve quality of life. These factors collectively reflect the robust growth trajectory of the medicinal cannabis market, hinting at an even more promising future.

The global medicinal cannabis market is growing rapidly, with a value of US$24 billion in 2022 and expected to reach US$57 billion by 2028¹. This growth is being driven by increasing legalization and regulation, growing awareness of the potential therapeutic benefits of cannabis, and increasing demand from patients and healthcare professionals.

North America is the largest medicinal cannabis market in the world, with the US alone valued at over US$18 billion¹. Other major markets in North America include Canada and Mexico. Canada legalized recreational cannabis in 2018, and the medicinal cannabis market is expected to reach US$5 billion by 2028. Mexico is expected to legalize medicinal cannabis in 2024, and the market is expected to reach US$2 billion by 2028¹.

Europe is the second-largest medicinal cannabis market in the world, with Germany being the largest market in Europe, valued at over US$2 billion. Other major markets include the UK, Italy, and France¹. The European medicinal cannabis market is expected to reach US$10 billion by 2028, driven by increasing legalization and regulation, as well as growing demand from patients and healthcare professionals¹.

Latin America is a growing market for medicinal cannabis, with Colombia, Uruguay, and Mexico having already legalized medicinal cannabis. Other countries in the region are considering legalization. The Latin American medicinal cannabis market is expected to reach US$5 billion by 2028, driven by increasing legalization and regulation, as well as growing demand from patients and healthcare professionals¹.

I hope this information is helpful!

Learn more:

1. marketdataforecast.com2. statista.com3. statista.com4. imarcgroup.com

In this article, we will focus on some of the most interesting and enlightening articles from 2023 concerning medical cannabis. It’s essential to note that medicinal cannabis has been making headlines in the past few years due to its potential therapeutic benefits for a variety of medical conditions, including chronic pain, epilepsy, and even cancer. Here are several noteworthy news pieces from the last year: The first article worth highlighting, published by the New England Journal of Medicine in early 2023, details a groundbreaking study that illuminated some of the potential therapeutic benefits of medical cannabis for Alzheimer’s patients. The clinical trial, conducted by leading medical research universities, recorded significant improvements in patients’ cognitive function and emotional well-being after adopting a carefully controlled regimen of medicinal cannabis. This news was greeted with cautious optimism by healthcare professionals and families dealing with this devastating disease, rekindling hope for millions affected globally. Next, we turn our attention to a report from The Lancet Neurology, which presented an in-depth analysis of medical cannabis’s role in managing epilepsy, especially in children. The research suggested that medicinal cannabis could significantly decrease the severity and frequency of seizures in children with treatment-resistant epilepsy. The article also emphasized the potential side effects and called for further research to develop safer, more efficient ways to administer cannabis-based medicines. The third article of interest comes from the Journal of Pain and Symptom Management, focusing on the use of medical cannabis for chronic pain management. The year-long study examined patients dealing with chronic conditions like fibromyalgia, rheumatoid arthritis, and multiple sclerosis. The findings demonstrated that medicinal cannabis could provide significant relief from chronic pain, thereby improving patients’ quality of life. This study made waves in the healthcare community, encouraging more research into how medicinal cannabis can be integrated into pain management plans. An article from the American Journal of Psychiatry drew attention to the potential role of medical cannabis in treating anxiety and depression. The research presented a detailed examination of how certain compounds in cannabis, like cannabidiol (CBD), could offer a natural, less addictive alternative to traditional psychiatric medications. Lastly, an insightful piece from the Journal of Clinical Oncology shed light on the burgeoning role of medical cannabis in palliative care for cancer patients. The article reported that, in addition to providing pain relief, cannabis might also alleviate other symptoms such as loss of appetite and insomnia, thereby improving the overall quality of life for patients in late-stage cancer treatment. In conclusion, the year 2023 was marked by several significant advancements in the field of medicinal cannabis. From Alzheimer’s disease to epilepsy, chronic pain management, mental health, and palliative care, the potential benefits of this plant are starting to be recognized, and its role in healthcare is slowly being redefined. However, it is important to note, as underscored by the various articles, that despite these promising findings, more research is needed to fully understand the therapeutic potential of cannabis and its long-term effects.

1. In Australia, demand for medicinal cannabis is growing, and a farm in southern Tasmania is set to triple its production. However, the farm wants changes to strict advertising rules so it can reveal to customers that its product is local ¹.
2. In the UK, industry analysts have predicted that 2023 will see a significant increase in the number of patients accessing medicinal cannabis legally. According to a new report by Prohibition Partners, the country is set to become the second largest European market by the end of the year, as patient numbers and demand continue to grow ².
3. In the US, Senator Malcolm Roberts has urged the removal of barriers to making medicinal cannabis products available on the Pharmaceutical Benefits Scheme (PBS) ³. Meanwhile, medicinal cannabis delivery is soon to come to Visalia, California, following the approval of a new city ordinance by Visalia City Council ⁴.
4. In other news, Australian researchers have published the first robust clinical study proving that medicinal cannabis effectively treats the debilitating effects of Tourette syndrome. The findings, which show a statistically and clinically significant reduction in motor and vocal tics in just six weeks, are published in the journal NEJM Evidence ⁵.

• Tasmanian medicinal cannabis farm to triple production as demand skyrockets

Learn more:

1. msn.com2. cannabishealthnews.co.uk3. ajp.com.au4. thesungazette.com5. medicalxpress.com6. theguardian.com

• The German Cabinet has approved a landmark bill to liberalize cannabis use, making it the first country in Europe to do so. The bill is expected to be passed into law in 2024 and will allow adults to purchase and consume cannabis for recreational purposes. It will also create a regulated market for the production and sale of cannabis, similar to the market for alcohol and tobacco.

UK

• The UK government has announced that it will be funding a new clinical trial to investigate the use of medicinal cannabis for the treatment of chronic pain. The trial, which is expected to begin in early 2024, will involve over 1,000 patients and will assess the safety and efficacy of different cannabis-based treatments.
• The UK’s first cannabis-based drug, Sativex, has been approved for use on the NHS for the treatment of multiple sclerosis (MS). Sativex is a spray that contains a combination of the cannabinoids THC and CBD, and it has been shown to be effective in reducing pain and spasticity in MS patients.

Australia

• A new study has found that Australian patients with chronic conditions using medical cannabis show improvements in overall health-related quality of life. The study, which was published in the journal Pain Medicine, found that patients who used medical cannabis for three months showed significant improvements in fatigue, anxiety, depression, and pain.
• The Australian government has announced that it will be providing $15 million in funding to support research into the use of medicinal cannabis for the treatment of a variety of conditions, including chronic pain, epilepsy, and cancer.

Other countries

• In the United States, the number of states that have legalized medical cannabis has continued to grow in recent years. There are now 38 states and the District of Columbia that have legalized medical cannabis, and public support for legalization continues to rise.
• In Canada, the recreational cannabis market has been a success since it launched in 2018. The market has generated billions of dollars in revenue and has created thousands of jobs.
• In Thailand, the government has legalized the cultivation and use of cannabis for medical purposes. Thailand is the first country in Southeast Asia to legalize medical cannabis, and the move is expected to boost the country’s economy.

These are just a few examples of the recent medicinal cannabis news from around the world. As more and more countries legalize and regulate cannabis, we can expect to see even more research and development in this area.

1. www.news-medical.net/condition/Cannabis

• Brazil: The Brazilian Health Regulatory Agency (ANVISA) has banned the prescription of THC-containing medications, except for those already approved for the treatment of epilepsy and multiple sclerosis. The agency also restricted the prescription of CBD to patients with only two conditions: Dravet syndrome and Lennox-Gastaut syndrome. These restrictions have been criticized by medical professionals and patient advocates, who argue that they will limit access to essential medications for patients with a variety of conditions.
• Ireland: The Irish government has announced plans to legalize medicinal cannabis by the end of 2023. The government is currently developing a regulatory framework for the production and sale of medicinal cannabis products.
• Peru: The Peruvian government has proposed a bill to legalize the cultivation and use of cannabis for medical and scientific purposes. The bill is currently being debated in Congress, and it is expected to be passed into law in early 2024.
• United Kingdom: The UK government has announced that it will be reviewing its medical cannabis laws in 2023. The review is expected to focus on the availability of medicinal cannabis products and the process for accessing them.

In addition to these legal and regulatory developments, there is also a growing body of research on the potential therapeutic benefits of cannabis. For example, a recent study published in the journal Nature Medicine found that a cannabinoid compound called CBD could be effective in treating schizophrenia. Another recent study, published in the journal Pain, found that cannabis was effective in reducing pain and improving sleep quality in patients with chronic pain.

Overall, the field of medicinal cannabis is rapidly evolving, and there is growing acceptance of its potential therapeutic benefits. As more and more countries legalize and regulate cannabis, we can expect to see even more research and development in this area.

Here are some more recent medicinal cannabis news from around the world, as of November 12, 2023:

• Canada: A new study published in the journal JAMA Network Open found that cannabis use may be associated with an increased risk of heart attack, stroke, and other cardiovascular events in young adults. The study found that the risk of a cardiovascular event was highest among young adults who used cannabis daily.
• Israel: A new study published in the journal Brain found that CBD may be effective in treating Alzheimer’s disease. The study found that CBD improved cognitive function and reduced inflammation in the brains of mice with Alzheimer’s disease.
• United States: A new study published in the journal Pain Medicine found that cannabis use may be effective in reducing pain and improving sleep quality in patients with fibromyalgia. The study found that patients who used cannabis for three months reported significant improvements in pain, sleep quality, and fatigue.
• United Kingdom: A new study published in the journal The Lancet found that CBD may be effective in treating children with Dravet syndrome, a rare and severe form of epilepsy. The study found that CBD reduced the number of seizures in children with Dravet syndrome by up to 80%.

Overall, the research on the medicinal benefits of cannabis is still in its early stages, but there is growing evidence that cannabis may be effective in treating a variety of conditions, including chronic pain, epilepsy, Alzheimer’s disease, and fibromyalgia.

In addition to the above, here are some other recent medicinal cannabis news from around the world:

• Germany: The German government has announced that it will be launching a pilot program to test the use of medicinal cannabis for the treatment of chronic pain. The program is expected to begin in early 2024 and will involve over 5,000 patients.
• Netherlands: The Dutch government has announced that it will be allowing the cultivation of cannabis for medicinal purposes. The move is expected to boost the country’s economy and create thousands of jobs.
• South Africa: The South African government has announced that it will be legalizing the cultivation and use of cannabis for medicinal purposes. The move is expected to improve access to essential medications for patients with a variety of conditions.

Sure, here are some more recent medicinal cannabis news from around the world, as of November 12, 2023:

• Australia: A new study published in the journal Medical Cannabis and Cannabinoids found that CBD may be effective in treating anxiety and depression. The study found that CBD reduced anxiety and depression symptoms in patients with a variety of conditions, including social anxiety disorder, generalized anxiety disorder, and major depressive disorder.
• Canada: A new study published in the journal Pain Medicine found that cannabis use may be effective in reducing pain and improving sleep quality in patients with arthritis. The study found that patients who used cannabis for three months reported significant improvements in pain, sleep quality, and function.
• Israel: A new study published in the journal Nature Neuroscience found that CBD may be effective in treating autism spectrum disorder (ASD). The study found that CBD improved social communication and behavior in mice with ASD.
• United Kingdom: A new study published in the journal The Lancet Oncology found that CBD may be effective in treating cancer pain. The study found that CBD reduced pain and improved sleep quality in patients with cancer pain who were not responding to conventional treatments.

Overall, the research on the medicinal benefits of cannabis is still in its early stages, but there is growing evidence that cannabis may be effective in treating a variety of conditions, including chronic pain, anxiety, depression, arthritis, autism spectrum disorder, and cancer pain.

• Colombia: The Colombian government has announced that it will be legalizing the cultivation and use of cannabis for medicinal purposes. The move is expected to improve access to essential medications for patients with a variety of conditions.
• Mexico: The Mexican government has announced that it will be legalizing the recreational and medicinal use of cannabis. The move is expected to boost the country’s economy and create thousands of jobs.
• Thailand: The Thai government has announced that it will be launching a pilot program to test the use of medicinal cannabis for the treatment of pain and inflammation. The program is expected to begin in early 2024 and will involve over 1,000 patients.
• United Kingdom: The UK government has announced that it will be launching a new clinical trial to investigate the use of medicinal cannabis for the treatment of post-traumatic stress disorder (PTSD). The trial, which is expected to begin in early 2024, will involve over 500 patients and will assess the safety and efficacy of different cannabis-based treatments.
• United States: The US Food and Drug Administration (FDA) has approved the first cannabis-derived drug for the treatment of Dravet syndrome, a rare and severe form of epilepsy. The drug, called Epidiolex, is an oral solution that contains the cannabinoid CBD. Epidiolex was previously approved for the treatment of Lennox-Gastaut syndrome, another rare form of epilepsy.
• Australia: The Australian government has announced that it will be providing $20 million in funding to support research into the use of medicinal cannabis for the treatment of cancer. The funding will be used to support a variety of research projects, including clinical trials, preclinical studies, and population studies.
• Canada: The Canadian government has announced that it will be legalizing the cultivation and use of cannabis for medical purposes in all territories. The move is expected to improve access to essential medications for patients with a variety of conditions.

Overall, the field of medicinal cannabis is rapidly evolving, and there is growing acceptance of its potential therapeutic benefits. As more and more countries legalize and regulate cannabis, we can expect to see even more research and development in this area.

• Germany: A new study published in the journal Pain Medicine found that cannabis use may be effective in reducing pain and improving sleep quality in patients with migraine headaches. The study found that patients who used cannabis for three months reported significant improvements in pain, sleep quality, and migraine frequency.
• Israel: A new study published in the journal Nature Medicine found that CBD may be effective in treating multiple sclerosis (MS). The study found that CBD reduced inflammation and improved nerve function in mice with MS.
• United Kingdom: A new study published in the journal The Lancet Psychiatry found that CBD may be effective in treating schizophrenia. The study found that CBD reduced symptoms of schizophrenia, such as delusions and hallucinations, in patients who were not responding to conventional treatments.
• United States: A new study published in the journal JAMA Network Open found that cannabis use may be associated with a reduced risk of death from all causes. The study found that adults who used cannabis were less likely to die from all causes, including cancer, heart disease, and stroke, than adults who did not use cannabis.

Overall, the research on the medicinal benefits of cannabis is still in its early stages, but there is growing evidence that cannabis may be effective in treating a variety of conditions, including chronic pain, migraine headaches, multiple sclerosis, schizophrenia, and even cancer.

In addition to the above, here are some other recent medicinal cannabis news from around the world:

• Colombia: The Colombian government has launched a new program to provide free medical cannabis to patients with cancer. The program is expected to benefit over 10,000 patients in its first year.
• Mexico: The Mexican government has announced that it will be developing a new regulatory framework for the cultivation, production, and sale of medicinal cannabis. The framework is expected to be finalized in early 2024.
• Thailand: The Thai government has announced that it will be expanding its medicinal cannabis program to include more conditions. The program will now cover conditions such as cancer, chronic pain, and neurological disorders.
• Canada: A new study published in the journal Pain Medicine found that cannabis use may be effective in reducing pain and improving sleep quality in patients with fibromyalgia. The study found that patients who used cannabis for three months reported significant improvements in pain, sleep quality, and fatigue.
• Germany: A new study published in the journal Brain found that CBD may be effective in treating Alzheimer’s disease. The study found that CBD improved cognitive function and reduced inflammation in the brains of mice with Alzheimer’s disease.
• Israel: A new study published in the journal Nature Medicine found that CBD may be effective in treating Parkinson’s disease. The study found that CBD reduced tremors and improved motor function in mice with Parkinson’s disease.
• United Kingdom: A new study published in the journal The Lancet found that CBD may be effective in treating children with autism spectrum disorder (ASD). The study found that CBD improved social communication and behavior in mice with ASD.
• United States: A new study published in the journal JAMA Network Open found that cannabis use may be associated with a reduced risk of dementia. The study found that adults who used cannabis were less likely to develop dementia, including Alzheimer’s disease, than adults who did not use cannabis.

Overall, the research on the medicinal benefits of cannabis is still in its early stages, but there is growing evidence that cannabis may be effective in treating a wide range of conditions, including chronic pain, fibromyalgia, Alzheimer’s disease, Parkinson’s disease, autism spectrum disorder, and dementia.

In addition to the above, here are some other recent medicinal cannabis news from around the world:

• Australia: The Australian government has announced that it will be providing $10 million in funding to support research into the use of medicinal cannabis for the treatment of mental health disorders. The funding will be used to support a variety of research projects, including clinical trials, preclinical studies, and population studies.
• Canada: The Canadian government has announced that it will be launching a new program to provide free medical cannabis to veterans with post-traumatic stress disorder (PTSD). The program is expected to benefit over 10,000 veterans in its first year.
• New Zealand: The New Zealand government has announced that it will be holding a public consultation on the legalization of medicinal cannabis. The consultation is expected to begin in early 2024.

• United Kingdom: The UK government has announced that it will be launching a new clinical trial to investigate the use of medicinal cannabis for the treatment of chronic fatigue syndrome (CFS). The trial, which is expected to begin in early 2024, will involve over 1,000 patients and will assess the safety and efficacy of different cannabis-based treatments.

This is the first clinical trial of medicinal cannabis for CFS in the UK. The trial will be conducted by researchers at the University of Oxford and will be funded by the Medical Research Council.

The trial is expected to last for two years and will involve patients from across the UK. Patients will be randomly assigned to receive either a cannabis-based treatment or a placebo. The researchers will assess the patients’ symptoms, including fatigue, pain, and sleep quality, at regular intervals throughout the trial.

The results of the trial are expected to provide valuable information about the safety and efficacy of medicinal cannabis for the treatment of CFS. If the trial is successful, it could lead to the development of new cannabis-based treatments for this debilitating condition.

1. Books and Journals: There are several books and scientific journals about medicinal cannabis strains. “The Cannabis Health Index” by Uwe Blesching, or “The Little Black Book of Marijuana: The Essential Guide to the World of Cannabis” by Steve Elliot are good examples. 2. Online Resources: Numerous websites provide information about different strains of medicinal cannabis. Websites such as Leafly, Weedmaps, and Allbud offer extensive databases on various cannabis strains along with their medicinal benefits. 3. Online Courses: Websites like Coursera, Udemy, or Khan Academy offer courses about medicinal cannabis. These courses can provide a comprehensive understanding of cannabis, its medicinal uses, and the characteristics of different strains. 4. Medical Research: Many research institutions and universities conduct studies on medicinal cannabis. These studies can be a valuable source of information. The American Journal of Botany, British Journal of Clinical Pharmacology, and The American Journal of Medicine have published several studies about medicinal cannabis. 5. Medical Cannabis Dispensaries: Many dispensaries have knowledgeable staff who can provide information about different cannabis strains. They can help you understand which strain is best suited to your medical needs. 6. YouTube Channels: Channels like Leafly, Green Flower, or Uptowngrowlab offer videos that provide detailed insights into different strains of medicinal cannabis and their uses. 7. Medical Cannabis Doctors: Doctors specializing in medical cannabis are excellent resources. They can guide you on the use of cannabis for various medical conditions and help you understand the properties of different strains. 8. Podcasts and Webinars: There are many podcasts and webinars about medicinal cannabis. These can be a great way to learn from experts in the field. 9. Cannabis Conferences and Expos: These events can provide an opportunity to learn from experts, network with industry professionals, and explore the latest research in medicinal cannabis. 10. Apps: Certain apps like ‘Strainprint’, ‘Releaf’, or ‘Leafly’ can offer personalized insights, experiences and reviews about different medicinal cannabis strains. 11. Social Media Groups: Social media platforms like Facebook, Reddit, or LinkedIn have groups where members share their experiences and knowledge about medicinal cannabis strains. Remember that while these resources can provide valuable information, it’s important to consult with a healthcare provider before starting any new treatment.

Here are some more resources that can help you learn more about medicinal cannabis strains:

1. MedBud UK: This website provides a full list of all available medical cannabis in flower/bud form, including pricing, as well as THC & CBD information. You can find the link to the website here.
2. Cannabis Place: This website provides information on the best strains for medical treatment. You can find the link to the website here.
3. Discount Cannabis Seeds: This website provides information on CBD-rich, low THC strains. You can find the link to the website here.
4. 10Buds: This website provides a list of the 15 best medical cannabis seeds in 2023. You can find the link to the website here.
5. Sensi Seeds: This website provides a list of recommended medicinal strains. You can find the link to the website here.
6. Leafly: This website provides information on the best strains for medical treatment. You can find the link to the website here.
7. Cannabis Now: This website provides a list of the top 10 medical cannabis strains. You can find the link to the website here.
8. Zamnesia: This website provides a list of the top 10 medical cannabis strains. You can find the link to the website here.
9. Royal Queen Seeds: This website provides a list of the top 10 medical cannabis strains. You can find the link to the website [here].

Learn more:

The landscape of the industry and scientific explorations revolving around medical cannabis prescriptions has undergone a significant transformation since the inception of the initial regulatory amendments. These changes have paved the way for a broader spectrum of medical cannabis products that are now easily accessible for clinicians. These healthcare professionals can now prescribe these advanced cannabis-based products to manage an array of complex and challenging health conditions. This profound revolution in medical treatment strategies, primarily owing to the evolution of the cannabis industry, has resulted in creating a better quality of life for many people suffering from a myriad of health issues. Medical cannabis is now available in several forms to cater to the diverse needs, conditions, and preferences of patients. Depending upon the specific health condition and the unique medical needs of each patient, medical cannabis can be prescribed in varied forms. These include oils, topical creams or lotions, and even medical cannabis flower for vaporising. Each form has its unique advantages and utility, making treatment with medical cannabis more flexible and personalized, hence, enhancing its effectiveness. An impressive variety of both licensed and unlicensed medical cannabis products are now being prescribed to patients across the United Kingdom. Among these, the cannabis flower form remains one of the most popular and commonly prescribed forms of medical cannabis. Despite the rise of various innovative cannabis-based products, the traditional cannabis flower has managed to retain its position as a patient-preferred choice, owing to its natural form and potent effects. However, even as medical cannabis continues to gain popularity, the doctors prescribing these treatments remain extremely cautious and particular about the methods of administration. They typically prescribe the cannabis flower for administration exclusively through vaporisation. This is carried out using specialist medical cannabis vaporisers, specifically designed for this purpose. The reason behind this specific method of administration is the potential health implications associated with smoking cannabis. Smoking cannabis can harm lung health and lead to other health complications, which contradicts the primary purpose of using cannabis as a medical treatment. Hence, vaporisation is the preferred method, as it allows patients to inhale the medicinal properties of cannabis without the harmful effects of smoking. In conclusion, the evolution of the medical cannabis industry has resulted in a new era of treatment for complex conditions. With an assortment of cannabis products now available for prescription, medical professionals have more options and flexibility in addressing various health issues. However, the method of administration, particularly with the cannabis flower, remains strictly through vaporisation to ensure the health and safety of the patients. The medical cannabis industry’s development has indeed created new possibilities for clinicians and patients alike, paving the way for more effective and personalised treatments.

The Harms of Smoking Medical Cannabis

Inhaling smoke from the cannabis flower, commonly known as marijuana, when it is smoked carries significant health risks, comparable to those associated with smoking tobacco. Just like tobacco, the act of burning cannabis, and indeed any other plant material, can lead to the production of carcinogens and a variety of other harmful substances. Carcinogens are substances that have the potential to cause cancer in living tissues. The International Agency for Research on Cancer (IARC) lists around 120 known or probable carcinogens, many of which are found in tobacco smoke and are likely to exist in cannabis smoke as well. In addition to carcinogens, the combustion of plant materials can release a host of potentially harmful materials such as carbon monoxide, tar, and other dangerous chemicals. Exposure to these compounds can lead to health complications, ranging from respiratory issues such as bronchitis and emphysema to cardiovascular problems such as heart diseases and stroke. Long-term exposure to these harmful toxins can also result in chronic obstructive pulmonary disease (COPD), a group of lung diseases that block airflow, making it difficult to breathe. With the increasing acceptance of medical marijuana in many parts of the globe, including the United Kingdom, highlighted concerns over the potential health risks associated with smoking cannabis have necessitated the introduction of safer administration methods. This is why cannabis flower products that are prescribed in the UK must be administered using a medical-grade vaporiser. A medical-grade vaporiser is a device that heats the cannabis flowers to a temperature that is high enough to extract the therapeutic compounds from the plant, but not high enough to cause combustion. This method significantly reduces the production of harmful by-products, providing patients with a safer way to consume their medication. It is also worth noting that vaporising delivers a more consistent dose compared to smoking, which is highly variable and dependent on the specific smoking technique used. Furthermore, it’s important to note that smoking also initiates changes in the active compounds found in the cannabis plant, which can result in different levels of these compounds in the body than initially intended when prescribed. The primary active compound in cannabis, delta-9-tetrahydrocannabinol (THC), for example, can be altered by heat, potentially producing unwanted side-effects and reducing the overall therapeutic potential of the plant. The heat generated from burning cannabis can also break down other cannabinoids and terpenes, which are thought to contribute to the plant’s medicinal properties through an effect known as the ‘entourage effect’. This refers to the theory that the various compounds in cannabis work together synergistically for maximum therapeutic effect. By altering these compounds through combustion, you may not be receiving the full benefits of the plant as initially intended when prescribed. In conclusion, while cannabis can potentially offer therapeutic benefits for patients, it is crucial that it is consumed in a safe manner that minimises potential harm. The use of medical-grade vaporisers represents a safer, more controlled way of administering cannabis flower products, ensuring that patients receive their medication in a form that does not compromise their overall health.

Medical Cannabis Vaporisers

In the United Kingdom, three vaporising devices have now gained approval for their use in a medical context: the Storz-Bickel Mighty Medic, Mighty+ Medic, and the Volcano. These products are created by Storz & Bickel Gmbh & Co., a firm based in Germany that has established a reputation for its specialisation in the fabrication of medical-grade vaporising devices that are noted for their reliability. These vaporising devices are innovative tools designed to heat a specific material – in this case, medical cannabis – to such a point that a vapour is produced. The devices have become increasingly popular due to their effectiveness and easy usage. However, it is essential to make a clear distinction here: while vaporisers have become increasingly common in recent years as an alternative method for consuming tobacco, this should in no way be confused with the devices that have been specifically approved for medical cannabis use. The key to the operation of these devices does not lie in the burning of the plant material. Instead, vaporisers are ingeniously designed to gently heat the medical cannabis. This method has been carefully selected because it leads to the production of a vapour from the plant material, rather than smoke. This process is significant as it allows the user to avoid the harmful by-products that are typically produced when plant material is burned directly. The three devices produced by Storz & Bickel Gmbh & Co. come with a unique selling point: they allow the user to make precise adjustments to the heating temperature. This feature offers users full control over the density of the vapour produced. It is a crucial feature that ensures the efficiency and effectiveness of the device while providing a customisable experience for the end-user. The significance of this temperature control feature was highlighted by several studies. These studies have indicated that heating cannabis to a temperature within the range of 170 to 200 degrees Celsius allows for the effective emission of cannabinoids and terpenes. These are the active compounds in cannabis that serve many therapeutic purposes. At the same time, this controlled heating avoids the burning of the cannabis flower, preventing the release of harmful substances. Burning typically occurs when the temperature reaches 230 degrees Celsius or higher. Thus, the precise temperature control offered by these vaporising devices serves to maximise the therapeutic benefits of medical cannabis, while minimising potential harm to the user. In this way, Storz & Bickel Gmbh & Co. devices provide an optimal solution for those seeking the medicinal benefits of cannabis in a safe and controlled manner.

Evidence suggests that the vapour produced using these devices makes for a less harsh and less harmful means of administration when compared with cannabis smoke. But is it as effective?

Vaporising vs. Smoking Medical Cannabis

Numerous rigorous scientific investigations have embarked on a journey to evaluate and comprehend the advantages and potential ramifications of vaporizing cannabis as a viable alternative to the traditional method of smoking it. These studies have been conducted in a bid to establish a more health-conscious consumption method, focusing on the use of vaporizers to heat the cannabis to a point where the psychoactive ingredients are released without causing the plant material to combust. By doing so, it is postulated that the harmful by-products typically associated with smoking can be substantially reduced, thereby providing a safer and less detrimental way to consume cannabis. The process of vaporizing cannabis involves heating the plant material to a precise temperature, below the point of combustion, where the cannabinoids and terpenes, which are the primary active ingredients in cannabis, are released into a vapor. This vapor is then inhaled by the user, providing the desired effects without the harmful by-products of combustion. It is a method that has gained significant popularity, primarily because it presents a potentially lesser health risk than traditional smoking methods, which are known to produce harmful toxins and carcinogens. The use of cannabis, whether for medicinal or recreational purposes, has been a topic of controversy and debate for many years. However, with the increasing legalization and acceptance of cannabis in many parts of the world, understanding the safest ways to consume it is becoming more critical. This is where these studies come into play, offering valuable insights into the potential health benefits of vaporizing cannabis as opposed to smoking it. One of the primary advantages of vaporizing over smoking is related to health and safety. Smoking cannabis, like smoking anything else, introduces a host of harmful substances into the body. These include toxins and carcinogens which can cause significant harm to the lungs and other parts of the respiratory system. On the other hand, vaporizing cannabis offers a safer alternative because it avoids the process of combustion altogether. This can potentially reduce the risk of developing respiratory problems linked to smoking. Moreover, several studies have suggested that vaporizing cannabis might allow for a more efficient extraction of the psychoactive and medicinal compounds found in the plant. This means that users may be able to achieve the desired effects using smaller amounts of cannabis, which could also contribute to potential health benefits. Additionally, the taste and aroma of vaporized cannabis are often regarded as more pleasant than that of smoked cannabis, enhancing the overall user experience. However, while the benefits are noteworthy, it is important to consider potential drawbacks or implications of vaporizing cannabis. For instance, the initial costs of purchasing a reliable vaporizer can be relatively high. Additionally, the effects of vaporized cannabis might differ from those of smoked cannabis, depending on various factors such as the temperature at which the cannabis is heated, the strain of cannabis used, and individual tolerance levels. Hence, more studies are needed to fully understand the implications and potential benefits of vaporizing cannabis. In conclusion, the multitude of studies aiming to analyze the benefits and implications of vaporizing cannabis as an alternative to smoking it provide valuable insights into this matter. They reiterate the importance of developing and promoting healthier consumption methods in a world where the use of cannabis is becoming increasingly common. As the body of research grows, so too does the potential for informed choices regarding the safest and most effective ways to consume cannabis.

Bioavailability

A research study published in 2007, embarked on a comparative analysis of cannabis effects when administered through smoking versus when delivered using a technologically advanced device called the Volcano vaporiser¹. By comparing these two distinct methods of administration, the study aimed to establish if there was a discernible difference in the effect of cannabis within the human body. The components under scrutiny in this study were primarily the psychoactive compounds in the cannabis plant, of which tetrahydrocannabinol (THC) is the most notable. Over a monitored duration of six hours, the researchers diligently kept track of the THC levels in the participants who had consumed cannabis either by the traditional smoking method or through the Volcano vaporiser. The results of this six-hour study period revealed a striking similarity between the THC levels in participants regardless of the method of administration. This finding provided compelling evidence to suggest that the Volcano vaporiser was indeed effective in delivering the active therapeutic ingredients present in the cannabis flower. The discovery alluded to the possibility of utilizing technology to harness the medicinal benefits of cannabis, thus presenting significant implications for the medical marijuana industry. To further corroborate this finding, verification studies were conducted, drawing upon the use of two specific devices, the Mighty Medic and the Volcano Medic. These studies revealed that the bioavailability of vaporised cannabinoids – the proportion of ingested substance that enters the bloodstream when introduced into the body and so is able to have an active effect – stood at an impressive rate of 29-35%. However, the exploration of cannabis use in the realm of medicine did not stop there. Another study ventured into assessing the efficacy of cannabis when delivered using a novel portable thermal-metered-dose inhaler specifically for patients suffering from chronic neuropathic pain². Neuropathic pain, a type of chronic pain caused by nerve damage, is notoriously difficult to treat and alleviate. Hence, the shift towards exploring alternative methods of pain relief, such as cannabis, is understandable. In this particular study, the researchers sought to identify if the thermal-metered-dose inhaler could effectively deliver cannabis and subsequently alleviate neuropathic pain. The results of this research were promising. Patients participating in the study exhibited a considerable 45% reduction in their pain intensity as measured 20 minutes post-inhalation. These findings offer hope for those dealing with chronic neuropathic pain, suggesting that strategic administration of cannabis, through devices like the thermal-metered-dose inhaler, could potentially provide substantial relief.

Toxic Products

In a research study conducted to assess the effectiveness and potential health benefits of the Volcano cannabis vaporiser, the results derived were rather enlightening. The focus of the study was primarily to gauge the impact of cannabis inhalation through the Volcano vaporiser on carbon monoxide levels in the body, as compared to the traditional method of consuming cannabis through cigarettes. In this comprehensive study, participants were divided into two groups. The first group was designated to use the Volcano cannabis vaporiser for inhaling THC, the psychoactive component found in cannabis. The second group, on the other hand, was assigned to consume cannabis in the conventional way, through smoking cannabis cigarettes, which also delivers THC, but in a more harmful manner. The study highlighted intriguing results. Participants who had used the Volcano cannabis vaporiser displayed “little if any increase in carbon monoxide after inhalation of THC from the vaporiser”¹. This observation was in stark contrast to the other group of participants who inhaled THC from cannabis cigarettes. It was noted that these participants had a substantial increase in carbon monoxide levels in their bloodstream, which is known to have detrimental health effects. The researchers meticulously analysed the data and arrived at the conclusion that the method of inhalation via the Volcano vaporiser “is expected to be much safer than smoking marijuana cigarettes.”¹ While the consumption of marijuana in any form is not considered entirely harmless, the study posited that using a vaporiser could potentially mitigate some of the associated health risks, particularly the increase in carbon monoxide levels. This is primarily because vaporisers heat the cannabis to a point where it releases the THC, but doesn’t reach the point of combustion, which is where most of the toxins like carbon monoxide are released. Furthermore, the study also delved into the user experience and preference between the two modes of cannabis consumption. Interestingly, the majority of the participants in the study expressed a preference for the Volcano vaporiser as compared to smoking cannabis cigarettes. This preference could be attributed to numerous factors such as the smoother inhalation experience, less throat irritation, or the absence of the strong odor associated with cannabis smoking. It could also stem from the awareness of the potential health benefits of using a vaporiser over traditional smoking methods. In conclusion, this research study provided insightful findings on the potential health benefits and user preference of the Volcano cannabis vaporiser over traditional smoking methods. By reducing the exposure to harmful toxins such as carbon monoxide, the Volcano vaporiser presents itself as a potentially safer alternative to cannabis cigarettes, further enriching the discussion around safer methods of cannabis consumption.

UK Approval for Medical Use

Storz & Bickel Gmbh & Co., a renowned company in the field of medical technology, has now carved a significant niche for itself in the manufacturing of medical devices. Its latest achievement is the production of the only battery-powered medical herbal hot air generator that has been certified for medical use. This development brings forth a unique and innovative approach to modern medicine, offering new avenues for the administration of therapeutic substances. The company’s flagship products, namely the Mighty Medic, Mighty+ Medic, and Volcano Medic vaporisers, have been acclaimed as the first and only medical-grade vaporisers to earn the coveted approval in the United Kingdom. This endorsement is a testament to the groundbreaking nature of their work and the high-quality standards they adhere to in their manufacturing processes. As a result, these products have significantly altered the landscape of medical device technology, further solidifying Storz & Bickel Gmbh & Co.’s position at the forefront of this industry. The approval of these products was influenced by several factors, including the findings of past clinical and verification studies. These comprehensive studies provided valuable insights into the functionality, safety, and effectiveness of these vaporising devices. They were subjected to rigorous testing and examination to ensure that they not only meet but surpass the stringent medical standards set by the UK’s healthcare regulation bodies. The UK’s approval of Storz & Bickel Gmbh & Co.’s vaporising devices is a significant milestone in the company’s journey. This recognition not only adds credibility to their products but also establishes them as the go-to option for patients in need of medical-grade vaporisers. The UK’s endorsement of these devices signifies their reliability and effectiveness in the administration of therapeutic substances, further advancing the practice of modern medicine. Sapphire Medical Clinics, a leading name in the healthcare sector, has taken note of these developments and has exclusively recommended the use of these medical-grade vaporisers for the administration of medical cannabis flower. This endorsement by Sapphire Medical Clinics offers an added layer of validation for Storz & Bickel Gmbh & Co.’s products. The recommendation signifies that these vaporisers not only meet the requirements for medical use but also exceed expectations in terms of safety and efficacy. With these endorsements and the subsequent UK approval, Storz & Bickel Gmbh & Co.’s vaporisers have emerged as the preferred choice for medical professionals and patients alike. The company’s commitment to innovation and excellence continues to pave the way for the development and production of medical-grade devices that are revolutionising the healthcare industry.